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1.1 Evaluation of the V-ATPase inhibitor Archazolid for treatment of T-
cell acute lymphoblastic leukemia 
1.1.1 Background 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy that is 
characterized by infiltration of the bone marrow with immature lymphoblasts that express T-cell 
surface markers (1). T-ALL accounts for 10%-15% of pediatric and 25% of adult acute lymphoblastic 
leukemia (ALL). T-ALL patients suffer from huge tumor burden, mediastinal enlargement and also 
have high risk of central nervous system (CNS) infiltration (1). These aggressive features in T-ALL 
make the treatment difficult and often result in poor prognosis. Thus, the cure rate of T-ALL had 
been lower than 10% for a long time due to high rate of relapse (1). Nowadays, various treatment 
approaches including aggressive-intensified combinational chemotherapy, radiotherapy, and stem 
cell transplants have improved the outcome of T-ALL treatment, with a 5-year event-free rate up to 
75% in children and more than 50% in adults (1). However, the treatment of T-ALL remains a 
problem in the clinic due to resistance and relapse (1). Although the detailed mechanisms that 
contribute to poor outcome of the disease remain elusive, activating mutations in Notch1 were found 
in more than 50% of T-ALL cases, highlighting Notch1 as a key player in T-ALL (1, 2). 
 
1.1.2 The Notch1 signaling pathway 
The Notch signaling pathway requires the binding of Notch ligand [Delta/Serrate/Lag2 (DSL) in 
invertebrates and Delta-like/Jagged in mammals] on the signal-sending cell to the Notch receptor on 
the receiving cell for activation. Ligand binding triggers two subsequent proteolytic cleavages of the 
Notch receptor: 1) the first cleavage, so called S2-cleavage, is mediated by ADAM family (also 
called TNF-α converting enzyme, TACE) metalloprotease and generates a short-lived truncated 
fragment NEXT (Notch extracellular trunction) (3); 2) the second cleavage, i.e. S3-cleavage of the 
membrane-bound NEXT fragment, is mediated by the γ-secretase complex and results in release of 
the Notch intracellular domain (NICD) from the plasma membrane. NICD translocates into the 
nucleus where it initiates transcription of Notch target genes. Afterwards, NICD is rapidly targeted 
by the FBW7-SCF ubiquitin ligase complex resulting in proteosomal degradation (4).  
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1.1.3  Notch1 as a target for T-ALL treatment  
Since γ-secretase is required for the S3-cleavage and thus Notch signaling activation, it is used as 
target to effectively block this oncogenic pathway. Inhibitors of γ-secretase (GSIs) have been 
developed for the treatment for Alzheimer’s disease as the protease is implicated in the processing 
of Amyloid precursor protein (APP) which mediates the pathogenesis of the disease (1). Several 
studies have shown that GSIs effectively inhibit Notch signaling and induce cell cycle arrest in T-
ALL cells harboring Notch1 activation mutations (2, 5, 6). However, several clinical trials 
investigating GSIs in T-ALL have shown that they exert mainly cytostatic effects and mostly failed 
to induce apoptosis (1, 2, 5) . Moreover, primary resistance to GSI treatment has been described (2, 
7). As resistance is a major problem in T-ALL therapy, novel strategies to inhibit Notch1 signaling 
with alternative mechanisms different from GSIs could represent promising approaches for T-ALL 
therapy. 
 
 
Figure 1.1  The Notch signaling pathway. 
Binding of Notch ligand DSL initiates proteolytic cleavage of the Notch receptor. The ADAM family 
metalloprotease mediates S2-cleavage, generating the substrate for S3-cleavage by γ-secretase complex, which 
releases Notch intracellular domain (NICD). Subsequently, NICD translocates into the nucleus where it 
interacts with DNA-binding protein CSL (CBF1, Su(Human) and LAG-1). The co-activator Mastermind like 
(MAML) is recruited to the NICD-CSL complex mediating transcription of Notch downstream targets. Image 
adapted from Jon C. Aster, 2008(4). 
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1.1.4 The V-ATPase as cancer target 
1.1.4.1 V-ATPase function and structure 
Vacuolar (V)H+-ATPase (V-ATPase) is a multimeric membrane protein complex that ATP-
dependently pumps protons across membranes and thereby regulates the pH of intracellular 
compartments as well as the cytoplasm (8). The organellar pH is strictly regulated and acidic pH is 
fundamental to various biological events such as membrane trafficking, the processing of receptor-
ligand complexes and the maintenance of lysosomal enzymatic activities (8-10). V-ATPase is located 
at the plasma membrane where it can either acidify extracellular environments such as around 
osteoclasts and renal cells (8, 11-13), or modulate cytoplasmic pH as in neutrophils and macrophages 
(8, 14, 15). 
 
Although the structure of V-ATPase (shown in Figure 1.2 ) is similar to that of F0F1-ATP-synthase 
(F-ATPase) (10), V-ATPase is not required for ATP synthesis. Eukaryotic V-ATPase is a membrane 
complex that consists of two domains working in a rotary mechanism (10, 16). The peripheral soluble 
V1 domain is located at the cytoplasmic side of the membrane, and possesses ATPase activity, i.e. it 
uses ATP as energy source to promote rotary movement. V1 consists of 8 different subunits (A-H) 
with multiple copies of some subunits. Three copies of each A and B subunits form a hexamer in a 
“ring-like” structure and the ATP binding site is located at the interface of the two subunits. The 
remaining subunits in the V1 domains are distributed between the peripheral (C, E, G, H) and central 
stalks (D, F) which connect V1 and V0 domains. They either pass the ATP-derived energy to a ring 
of proteolipid subunits in V0 serving as rotor or stabilize A3H3 hexamer-ring as a stator. 
The membrane bound V0 domain is responsible for translocation of protons across the membrane (9, 
11, 15). The V0 domain contains six different subunits (a,d,e,c,c’ and c’’). The hydrophobic 
membrane-embedded proteolipid subunits (c, c’ and c’’) form a ring (17) and each contains a buried 
Glu residue which is important for proton transport (10). Another crucial player of proton transport 
is the subunit a which hypothetically provides two H+ half channels that work together with the c, 
c’and c’’ subunits (18). Protons enter the inner half channel and bind to buried Glu residues in the c-
subunits. This is followed by rotation of the c subunits for nearly 360 degree and protons get 
transferred to a buried Arg (R735) residue within subunit a. Subsequently, the protons get then 
transferred to the outer half channel which is lined by buried charged residues on the C-terminal 
domain of subunit a and exit the membrane (10, 11). 
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Figure 1.2: Structure of the V-ATPase 
V-ATPase is a membrane-bound multimeric proton-translocating protein complex. V-ATPase is mainly 
composed of two domains, a peripheral V1 domain and a membrane integrated V0 domain. The V1 domain 
mediates ATP hydrolysis which provides energy for the rotary motion that is subsequently passed to the c-ring. 
Protons can enter the half-channel of the a-subunit in the V0 domain and thereafter bind to a Glu residue in the 
c-subunit. Rotation of the c-ring passes protons to the outer half-channel on the a-subunit, resulting in release 
of protons into the lumen. Image is adapted from Forgac, 2007(11). 
 
1.1.4.2 V-ATPase inhibitors 
Recent studies have demonstrated that V-ATPase is overexpressed in some types of cancer (19-21) 
and contributes to tumor metastasis, survival and growth (22, 23) . Therefore, V-ATPase inhibition 
represents an interesting anti-tumor target. Nowadays, only few V-ATPase inhibitors are known. 
Achieving a better understanding in the mode of action of the enzyme and its inhibitors would help 
to develop new drugs that might be promising anti-tumor therapeutics (24). 
 
Class ONE: Plecomacrolides. 
The plecomacrolide V-ATPase inhibitors bafilomycin and concanamycin were isolated from 
Streptomyces species in the early 1980s (25-28). The investigation of their structure-activity 
relationships has been intensively conducted (29-33). In the early 1990s, several studies 
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demonstrated that their V-ATPase binding site is located in the V0 domain (34). These findings were 
further corroborated by amino exchanges and radioactive labeling (cross-linking) studies, proving 
that plecomacrolides interact with the V0 c-subunit (35, 36). 
 
Class TWO: Benzolacton Enamides 
A new class of compounds, sharing a benzolactone enamide core structure, had entered the field in 
the late 1990s. Benzolacton enamides were found in different natural sources ranging from marine 
macroorganisms such as Haliclona sp. (salicylinhalamides) or Aplidium lobatum (lobatamides) to 
microorganisms such as the gram negative bacterium Pseudomonas sp. (oximidines) or the 
myxobacterium Chondromyces sp. (apicularens) (24, 37-40). These substances were demonstrated 
to be highly cytotoxic and showed a V-ATPase inhibition pattern similar to that of the 
plecomacrolides (24, 37-41). 
 
Class THREE: Indolyls 
Structure activity studies based on bafilomycin led to the discovery of major structural elements for 
V-ATPase inhibition (32) which allowed the identification of indole derivatives as structurally 
simplified V-ATPase inhibitors (42). The most potent one in this class of substances, referred to as 
INDOL0, showed V-ATPase inhibition in chicken osteoclast with an IC50 of 30 nM (43). INDOL0 
has been shown to interact with subunit c of V-ATPase (44, 45) with a similar mode of inhibition as 
bafilomycin. 
 
Class FOUR：New players: Archazolids 
Archazolid was first isolated from myxobacteria Archangium gephyra and Cystobacter violaceus (46, 
47). Archazolid contains a macrocyclic lactone ring bearing a thiazole side chain (24, 46, 47). Initial 
screening of biological activity of novel antibiotics originated from myxobacteria led to the discovery 
of Archazolid that later showed highly growth inhibitory effect in a set of mammalian cell lines due 
to V-ATPase inhibition (24, 47). Further studies confirmed V-ATPase as target of Archazolid with 
an IC50 in the nanomolar range (48).  
Even though F-ATPases and Na+/K+-ATPases share structural similarity with V-ATPase, the effect 
of Archazolid was proved to be specific for V-ATPase. Moreover, Archazolid competes with the 
concanamycin binding site located in the V0 subunit c (48). 
During recent years, our group has studied the function of Archazolid in invasive metastatic cancer 
cells and has elucidated that Archazolid A inhibited cell motility and induced apoptosis (49-51).  
Archazolid has attracted attention as highly potent V-ATPase inhibitor that exerts promising anti-
tumor and anti-metastatic effects (49-51). 
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Figure 1.3 Chemical structure of Archazolids. 
Image was adapted from Hassfeld, J. et al 2006 (52). 
1.1.4.3 Aim of the study  
It was shown recently that γ-secretase-mediated S3 cleavage of the Notch receptor occurs at 
endosomal compartments and requires low pH (53, 54). Moreover, reduced acidification of the endo-
lysosomal system by inhibition of the vacuolar H+-ATPase (V-ATPase) impaired Notch processing 
and signaling activity (53, 55). 
Interestingly, lysosome disruption has been shown to exert anti-leukemic effects which were based 
on increased lysosomal size and biogenesis in acute myeloid leukemia (AML) (56). 
Along this line, this study aimed to investigate whether inhibition of V-ATPase by Archazolid A 
could inhibit Notch signaling in a way different from GSI and therefore might be an alternative 
strategy for leukemia treatment. 
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1.2 Evaluation of Cdk5 as target for breast cancer treatment 
1.2.1 Breast cancer and its treatment 
Breast cancer represents one of the most common cancer types among women, and its incidence is 
increasing every year. For many years, the treatment of breast cancer had solely depended on 
cytotoxic chemotherapy (57). Nowadays, conventional treatment of breast cancer involves surgery, 
radio- and chemotherapy leading to markedly reduced mortality (58). Notably, the treatment of breast 
cancer has evolved to a more tailored, target-directed therapy, based on the presence of estrogen 
receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/Neu, also 
known as ErbB2, a member of the epidermal growth factor receptor family) (57, 59, 60). The 
blockade of EGF to HER2/Neu receptor by the therapeutic monoclonal antibody Trastuzumab 
(Herceptin®, Roche) increased survival of patients with HER2-overexpressing breast cancer (61-63). 
However, response to Herceptin therapy is limited due to its requirement for HER2 expression.  
Despite the major progress achieved in breast cancer treatment in the past years, the treatment of 
“triple-negative” breast cancer, which lacks the expression estrogen receptor, HER2/Neu and 
progesterone receptors, was rather unsuccessful. Triple-negative breast cancers are very aggressive, 
and have the poorest prognosis amongst the different subtypes. Due to the absence of these three 
major targets of conventional treatment, fighting this type of breast cancer requires combined 
therapies and effective treatment options are strongly limited. Therefore, it is of great importance to 
identify alternative novel targets for the treatment of breast cancer.  
1.2.2 Breast cancer stem cells 
 
During recent years, research indicated that the high relapse rate of aggressive breast cancers is 
associated with a small subpopulation of breast cancer cells, i.e. breast cancer stem cells (CSCs). 
Breast CSCs have the characteristic of CD44+/CD24-/low mesenchymal phenotype, undergo 
asymmetric cell division, show high tumor-initiating potential, and are resistant to common 
therapies(64). There is growing evidence that CSCs are the main cause for cancer relapse and 
metastasis formation. It was shown that “successful” metastasis formation requires the CSC to 
migrate from the primary tumor followed by establishment of metastasis in a secondary site (65). 
The epithelial to mesenchymal transition (EMT) is a well-coordinated and multistep process during 
which epithelial cells lose their epithelial properties and acquire mesenchymal characteristics (65). 
This process is critical for embryonic development when cells change their morphology, lose cell-
cell adhesion and cell polarity, and acquire migratory and invasive characteristics (66). There is 
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growing body of evidence that the abnormal activation of the EMT developmental program 
contributes to tumor metastasis and that this process enables tumor cells to migrate from their primary 
site and also promotes their ability of self-renewal(66-68). Thus, EMT was reported to be essential 
for CSCs formation and maintaining “stemness” (69-71). 
Thus, EMT plays a fundamental role in metastasis, therapy resistance, and tumor recurrence by 
causing CSC formation(65). After chemotherapy, residual tumors have been shown to be enriched 
in CSCs and possess gene signatures with hallmarks of EMT like properties (64, 72, 73). 
 
Therefore, targeting breast CSCs/EMT may be an attractive strategy to treat resistant and recurrent 
breast cancers and might improve breast cancer therapy and patient prognosis. 
1.2.3 Cyclin dependent kinase 5 (Cdk5) 
1.2.3.1 Cdk5 and its functions  
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine/threonine kinase which was discovered 
in 1992 and is structurally related to Cdc2/Cdk1, sharing approximately 60% sequence identity (74-
77). Cdk5 is a unique member of the Cdk family. Unlike classical mitotic Cdks, Cdk5 is not mainly 
involved in controlling cell cycle transitions, but is highly expressed in neuronal tissues where it 
exerts important functions. Cdk5 is important for the layering of the CNS during development (78), 
i.e. Cdk5 knockout mice die perinatally and show severe defects in neuronal positioning. In a cellular 
context, Cdk5’s function in neurons is well studied: Cdk5 regulates actin dynamics, neuronal 
migration, adhesion, membrane transport and synaptic processes (79, 80). Deregulation of neuronal 
Cdk5 contributes to neurodegenerative diseases, amongst them Alzheimer’s disease, where 
constitutively active Cdk5 results in hyper-phosphorylation of tau (81, 82). Due to its high abundance 
and importance in the CNS, Cdk5 was thought to be neuron-specific for a long time. However, 
recently, non-neuronal functions of Cdk5 gained attention and Cdk5 has been shown to be implicated 
in regulating cell migration, cell death and survival in peripheral tissues (83-85). 
 
1.2.3.2 Cdk5 inhibitor (R)-Roscovitine 
Characterization of 2,6,9-trisubstituted purines led to the discovery of Cdk inhibitors (86-88), 
amongst them Roscovitine. It is a close analogue to olomoucine, one of the first 2,6,9-trisubstituted 
purine Cdk inhibitors, but exerts increased potency and selectivity towards Cdk5 (88). Roscovitine 
acts only on Cdk1, Cdk2, Cdk5, Cdk7 and Cdk9 (IC50 below 1μM) to a relevant degree (88). Further 
structure-activity studies have shown that (R)-Roscovitine (Seliciclib, CYC202) is more potent than 
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its (S)-stereoisomer in inhibiting cdc2/cyclin B (87). Since it was discovered, studies have shown 
that Roscovitine exerts anti-mitotic and pro-apoptotic effects in various types of tumors (89). Also, 
by inhibiting Cdk5 activity, Roscovitine functioned cell cycle-independently, showed anti-
angiogenic and anti-inflammatory effects (84, 85) and inhibited cell motility (90). 
 
1.2.4 Aim of the study 
A tissue microarray (TMA) from 204 patient samples with various types and stages of breast cancer 
was analyzed in collaboration with Prof. Dr. Doris Mayr and Dr. Elisa Schmoeckel (Institute of 
Pathology, LMU, Munich). Immunohistochemical staining of the TMA indicated an involvement of 
Cdk5 in breast cancer. As shown in Figure 1.4, breast cancer cells showed markedly higher 
expression of Cdk5 comparing to normal breast tissue.  
 
 
 
Figure 1.4 Immunostainings for Cdk5 in healthy and breast cancer samples are shown. (A) Staining of 
Cdk5 in healthy mamma tissue is shown. (B) Breast cancer tissues shown an increased Cdk5 staining. 
 
Therefore, the aim of this study was to elucidate the function of Cdk5 in breast cancer progression, 
focusing on tumor cell growth, motility as well as effects on breast cancer stem cells. 
 
 2 Materials and Methods 
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2.1 Materials 
2.1.1 Compounds 
(R)-Roscovitine was obtained from Sigma-Aldrich. 
Archazolid A was purified, isolated as described previously (47) and provided by the group of Rolf 
Müller. 
The γ-secretase inhibitor Dibenzazepine (DBZ) was purchased from Merck (Darmstadt, Germany). 
The compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at -20℃. For experiments, 
compounds were freshly diluted in culture medium. The final concentration of DMSO didn’t exceed 
0.1%. 
 
 
 
Figure 2.1 Chemical structures of (R)-Roscovitine, Archazolid A and DBZ are shown. 
2.1.2 Biochemicals, inhibitors, dyes and cell culture reagents 
 
Table 2.1: Biochemicals, inhibitors, dyes and cell culture reagents. 
Reagent Producer 
Accustain® paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen, Germany 
B27® Supplement (50×) Life technologies, Carlsbad, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent, Roti-Quant® Carl-Roth, Karlsruhe, Germany 
CellTiter-Blue® Promega, Manheim, Germany 
CellTracker™ Green CMFDA Life technologies, Carlsbad, USA 
Chromium(III) potassium sulfate 
dodecahydrate Merck, Darmstadt, Germany 
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Collagen G Biochrom AG, Berlin, Germany 
CompleteTM mini EDTA free Roche diagnostics, Penzberg, Germany 
Crystal violet  Carl Roth, Karlsruhe, Germany 
Cyclohexylamino-1-propane  
sulfonic acid(CAPS) Merck, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreithol (DTT) AppliChem, Darmstadt, Germany 
DMEM (high glucose) PAA Laboratories, Pasching, Austria 
Dulbecco’s Modified Eagle Medium (DMEM) PAA Laboratories, Pasching, Austria 
EDTA Carl Roth, Karlsruhe, Germany 
Epidermal growth factor, human (hEGF) Peprotech, Rocky Hill, USA 
Fetal calf serum gold (FCS gold) PAA Laboratories, Pasching, Austria 
Fibroblast growth factor-basic, human (bFGF) Peprotech, Rocky Hill, USA 
FluorSaveTM Reagent mounting medium Merck, Darmstadt, Germany 
Gelatin (Type A) From Porcine Skin Sigma-Aldrich, Steinheim, Germany 
Glutamine Sigma-Aldrich, Taufkirchen, Germany 
Glycine Sigma-Aldrich, Taufkirchen, Germany 
Hoechst (bisBenzimide H33342) Sigma-Aldrich, Taufkirchen, Germany 
LysoTracker® dye  Molecular Probes, Darmstadt, Germany 
MEGMTM Bullet Kit Lonza, Basel, Switzerland 
Methylcellulose  Sigma-Aldrich, Taufkirchen, Germany 
Na3VO4 ICN Biomedicals, Aurora, Ohio, USA 
NaF Merck, Darmstadt, Germany 
Non-fat dry milk powder (Blotto)  Carl Roth, Karlsruhe, Germany 
Page RulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin 100× PAA Laboratories, Pasching, Austria 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Munich, Germany 
Poly(2-hydroxyethyl methacrylate)  
(Poly-HEMA) Sigma-Aldrich, Taufkirchen, Germany 
Polyacrylamid (Rotiphorese® Gel A 30%) Carl Roth, Karlsruhe, Germany 
Propidium iodide (PI) Sigma-Aldrich, Taufkirchen, Germany 
Puromycin Dihydrochloride,  
ready made solution Sigma-Aldrich, Taufkirchen, Germany 
Pyronin Y Sigma-Aldrich, Taufkirchen, Germany 
Pyruvate PAA Laboratories, Pasching, Austria 
2 Matierials and methods  
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RPMI 1640 PAN Biotech, Aidenbach, Germany 
Tris-Base Sigma-Aldrich, Taufkirchen, Germany 
Tris-HCl Sigma-Aldrich, Taufkirchen, Germany 
Trisodium citrate Carl Roth, Karlsruhe, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween®20 AppliChem, Darmstadt, Germany 
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
 
 
Table 2.2: Commonly used buffers       
PBS+ Ca2+/Mg2+ (pH 7.4) PBS (pH 7.4) 
NaCl 137 mM NaCl 132.2 mM
KCl 2.68 mM Na2HPO4 10.4 mM
Na2HPO4 8.10 mM KH2PO4 3.2 mM
KH2PO4 1.47 mM H2O 
MgCl2 0.25 mM  
H2O   
 
 
 
Trypsin/EDTA (T/E)  Collagen G 
Trypsin  0.05%  Collagen G 0.001%
EDTA  0.20%  PBS  
PBS      
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2.1.3 Technical equipment 
Table 2.3 Technical equipment 
Name Device Producer 
ABI 7300 RT-PCR Real-time PCR system Applied Biosystems, Foster City, USA 
Axiovert 25 / 200 Inverted microscope Zeiss, Jena, Germany 
Canon EOS 450D Digital camera Canon, Tokio, Japan 
Culture flasks, plates, dishes Disposable cell culture material TPP, Trasadingen, Switzerland
FACSCalibur Flow cytometer Becton Dickinson, Heidelberg, Germany 
Hera Cell Incubator Heraeus, Hanau, Germany 
IBIDITM μ-slide Microscope slide Ibidi GmbH, Munich, Germany 
Leica TCS SP8 Confocal laser scanning microscope Leica, Wetzlar, Germany 
LSM 510 Meta Confocal laser scanning microscope Zeiss, Jena, Germany 
Megafuge 1.0s Centrifuge Heraeus, Hanau, Germany 
Mikro 22R Table centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® ND-1000 Spectrophotometer Peqlab,Wilmington, USA 
Olympus DP25 Microscope Biological microscope Olympus, Hamburg, Germany
Primus 25 advanced Thermocycler Peqlab, Wilmington, USA 
SpectraFluor PlusTM Microplate multifunction reader 
Tecan, Männedorf, 
Switzerland 
TB1 Thermoblock Biometra, Göttingen, Germany
Vi-CellTM XR Cell viability analyzer Beckman Coulter, Fullerton, CA, USA 
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2.2 Methods  
2.2.1 Cell culture 
The human breast cancer cell line MDA-MB-231 was purchased from CLS cell lines service GmbH 
(Eppelheim, Germany) and maintained in DMEM supplemented with 10% fetal calf serum (FCS) 
(PAA Laboratories, Cölbe, Germany).  
Human leukemia Jurkat T cells (J16) (S-Jurkat) were kindly provided by P.H. Krammer and  
H. Walczak (Heidelberg, Germany). S-Jurkat cells were cultured in RPMI 1640 medium (PAN 
Biotech, Aidenbach, Germany) supplemented with 10% FCS and 1% sodium pyruvate (PAA 
Laboratories, Pasching, Austria). CEM (CCRF-CEM) cells were  kindly provided by Dr. Joachim 
Arend (Mainz, Germany). CEM cells were cultured in RPMI 1640 medium supplemented with10% 
FCS.  
All cell lines were cultivated at 37°C with 5% CO2 in a humidified incubator.  
MDA-MB-231 cells were passaged (1:10) every 3-4 days. Therefore, the growth medium was 
removed and the cells were washed with pre-warmed PBS. Cells were detached by incubating with 
2ml Trypsin/EDTA for 5 min at 37℃ . To terminate trypsin reaction, 7ml stopping-medium 
containing FCS was added. Subsequently, cells were centrifuged and supplied with fresh medium.  
Leukemia cell lines were passaged every 2-3 days. S-Jurkat cells were maintained at a density below 
1×106 cells/ml. CEM cells were maintained at a density below 2×106 cells/ml.  
The cell lines were used up to passage 25. 
 
Table 2.4 Growth medium for different cell lines 
MDA-MB-231 growth medium  CEM growth medium 
DMEM 500 ml  RPMI 1640 500 ml
FCS gold 50 ml  FCS gold 50 ml
Pen / Strep* 5 ml  Pen / Strep* 5 ml
 
 
MDA-MB-231 shRNA-clones medium  S-Jurkat growth medium 
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DMEM 500 ml  RPMI 1640 500 ml
FCS gold 50 ml  FCS gold 50 ml
Pen / Strep* 5 ml  Pen / Strep* 5 ml
Puromycin (10 mg/ml)  55 µl  Sodium pyruvate  1%
* Pen / Strep: Penicillin 10 000 Units/ml, Streptomycin 10 mg/ml 
2.2.2 Seeding for experiments 
MDA-MB-231 cells were seeded (1:3-1:5) in multiwell plates for experiments up to 48 h. 
Leukemia cell lines were seeded at 5×105 cells/ml (for experiments up to 24 h) or at 1×105 cells/ml 
(for experiments up to 48 h).  
 
2.2.3 Freezing and thawing 
Nitrogen stocks were prepared for each cell line. For MDA-MB-231 cells, cells were detached by 
Trypsin/EDTA and collected by centrifugation. Suspension cells were collected by centrifugation. 
Cells were resuspended in freezing medium (70% normal medium for each cell line, 10% DMSO 
and 20% additional FCS), transferred to cryovials  (2-4×106 cells in 1.5 ml per vial) and kept at  
-80°C and transferred to liquid nitrogen (-196°C) after two days for long-term storage. 
 
2.3 Proliferation Assay  
2.3.1  Proliferation assay for breast cancer cells using crystal violet staining 
 
MDA-MB-231 cells were seeded in 96-well plates (1,500 cells per well). After overnight incubation, 
cells in a reference plate were stained with crystal violet and served as initial control. The cells in a 
treatment plate were either left untreated or treated with indicated concentrations of Roscovitine for 
72 h. After treatment, the medium was removed and cells were stained with crystal violet for 10 min, 
RT. Afterwards, the plate was rinsed with water to remove free crystal violet and was dried overnight. 
Cell-bound crystal violet was dissolved with sodium citrate buffer and the absorbance which 
correlates with cell number was measured at 550nm using a SpectraFluor PlusTM (Tecan, Männedorf, 
Switzerland) plate reader. For statistical analysis, cells treated with vehicle control were set to 100%. 
2 Matierials and methods  
 
18
 
Table 2.5 Crystal violet and sodium citrate buffer. 
Crystal violet staining solution  Sodium citrate buffer 
Crystal violet 0.5%  Na3C6H5O7 0.05 M
Methanol 20%  Ethanol 50%
H2O  H2O 
2.3.2 Proliferation assay for leukemia cells by CellTiter-Blue® Assay 
 
S-Jurkat and CEM cells were collected by centrifugation and subsequently resuspended in culture 
medium at 3×104 cells/ml. 100 μl of the cell suspension was seeded into a 96-wells. The next day, 
Archazolid A and DBZ were added. After 70 h of incubation, 20μl CTB solution was added and 
incubated at 37℃ for further 2h. Fluorescence (550Ex/590Em) was measured using a SpectraFluor 
PlusTM (Tecan, Männedorf, Switzerland) plate reader. For statistical evaluation, cells with vehicle 
control were set to 100% viable cells. 
2.4 Flow cytometry 
 
Flow cytometry (FCM) was used for the analysis of cell death, apoptosis and cell cycle. 
Measurements were performed using a FACS Calibur (Becton Dickinson, Heidelberg, Germany).  
 
Table 2.6 FACS buffer for FACSCalibur  
Sheath fluid (pH 7.37) 
NaCl  8.12 g
KH2PO4  0.26 g
Na2HPO4  2.35 g
KCl  0.28 g
Na2EDTA  0.36 g
LiCl  0.43 g
NaN3  10 mM
H2O  ad 1,000 ml
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2.4.1  Quantification of cell death  
 
Quantification of cell death was either performed according to Nicoletti et al (91) or by propidium 
iodide (PI) exclusion.  
 
2.4.1.1 Quantification of apoptotic cell death and cell cycle analysis using the Nicoletti 
assay. 
 
Cells (1×105 cells/ml was used for 24 h and 48 h experiments; 5×104 cells/ml was used for 72 h 
experiments) were seeded in 24-well-plates and stimulated with the respective substances for 
indicated times. After stimulation, cells were collected by centrifugation (600 xg, 10 min, 4℃). 
Supernatants were discarded and pellets were washed with PBS twice. For PI staining, cell pellets 
were resuspended in HFS-solution containing PI (50μg/ml) and incubated at 4℃ overnight followed 
by analysis via flow cytometry the next day. 
 
Table 2.7 HFS solution 
HFS  solution 
Sodium citrate 0.1%
Triton X-100 0.1%
PBS Add 1 ml
 
 
Figure 2.2: Analysis of apoptotic cells and cell cycle. 
0
100
200
300
400
Co
un
t
G0/G1
S
G2/M
PI fluorescence signal
2 Matierials and methods  
 
20
Since PI quantitatively stains DNA, the fluorescence intensity depends on the respective DNA content of the 
cell. As the DNA content changes during duplicating, the different stages (G0/G1-phase, S-phase, G2/M-phase) 
during cell cycle can be distinguished, i.e. the fluorescence intensity of the cells in G2/M-phase would be twice 
as high as that of cells in the G0/G1-phase. In the S-phase, fluorescence intensity is between the G0/G1 and G2/M. 
When cells undergo apoptosis, DNA gets condensed and fragmented, resulting in the sub-G0/G1 peak left of 
the G0/G1 peak. The relative amount of cells in different cell cycle phases was quantified using the FlowJo 7.6 
analysis software (Tree Star Unc., Ashland, USA). 
 
2.4.1.2 PI exclusion assay for leukemia patient samples 
Leukemia patient samples were obtained from Helmholtz Center Munich. 
Cells were collected by centrifugation and resuspended in RPMI 1640 medium supplemented with 
20% FCS, 1% Glutamine and Penicillin/Streptomycin. Cell number was adjusted to 1×106 cells/ml 
and 100μl of cell suspension per wellwere seeded into 96-well-plates. Tested substances were diluted 
to 2-fold end concentration in culture medium, and 100 μl were added to the cells. Medium with the 
same amount of DMSO was used as control. After treatment for 48 h, cells were stained with 300 μl 
PI-PBS solution (end concentration 5 μg/ml) before incubation for 5 min in the dark on ice followed 
by analysis via flow cytometer. Cells with high PI intensity were considered dead. 
 
2.5 Colony formation assay 
2.5.1 Colony formation assay for adherent breast cancer cells 
MDA-MB-231 cells were seeded and stimulated with Roscovitine (10 μM, 20 μM, 30 μM) for 24 h. 
For Cdk5 silencing, nt or Cdk5 siRNA transfected cells were seeded 24 h after transfection. Nt or 
Cdk5 shRNA cells were directly seeded.  
After treatment, cells were trypsinized and 5,000 cells per well were seeded in a 6-well plate. The 
cells were allowed to grow for 7 days. Cells were stained with crystal violet for 10 min. The plate 
was rinsed with water to remove free crystal violet and dried overnight. Representative pictures from 
each treatment were taken. Cell-bound crystal violet was dissolved with sodium citrate buffer and 
the absorbance which correlates with cell number was measured at 550nm at the SpectraFluor PlusTM 
(Tecan, Maennedorf, Switzerland) plate reader. For statistical analysis, cells treated with vehicle 
control were set to 100%. 
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2.5.2 Colony formation assay for leukemia cell lines 
Leukemia cells were adjusted to 5×105 cells/ml, and 1ml of the cell suspension was added to a 6-
well and stimulated with Archazolid A and DBZ for 24 h. Cells were washed once with PBS and 
resuspended in 1.5 ml culture medium. After counting and adjusting the cell number to 5×105 cells/ml, 
100 μl of the suspension were mixed with 900μl colony formation assay medium, vortexed and 
seeded (100 μl) into 96-well-plates (3 wells per treatment). Then the plates were incubated for 11days 
in the incubator. After treatment, images from each well were taken with a Zeiss 510 Meta Confocal 
Microscope. Colonies formed with more than four cells were counted with Image J (NIH, USA) 
using the cell counter plugin.  
 
Table 2.8 Colony formation assay medium for leukemia cell lines 
RPMI 1640 Medium  
FCS gold 40%
Methylcellulose (0.52%)
Sodium pyruvate  
(included only for S-Jurkat Cells) 
1%
 
2.6 Cell motility assays  
Transwell® permeable supports (8 μm pore size, 6.5 mm inserts) were used according to the 
manufacturer’s instructions. The transwell inserts were coated with collagen G for transwell 
migration assay or with Matrigel® for invasion assay. Transwell inserts were placed into 24-well 
plates containing 700μl DMEM with 0.1% BSA (negative control, -Co), or 700 µl DMEM containing 
10% FCS and 0.1% BSA (positive control, +Co). 1×105-3×105 cells labeled with CellTracker™ 
Green CMFDA were added to the inserts, and allowed to migrate for 16 h. In the experiment with 
Roscovitine, MDA-MB-231 cells were pretreated with Roscovitine for 24 h and allowed to migrate 
in the presence of Roscovitine in both upper and lower chamber. After 16 h of migration, the non-
migrated cells in the upper chamber were removed with cotton swab. Then the inserts were put in 
the wells 24-well plate containing PBS+( Ca2+/Mg2+). Pictures of each inserts were taken using a 
Axiovert 25/200 microscope (Zeiss, Jena, Germany). Four pictures from each group were taken and 
cell numbers were counted with Image J using the cell counter plugin. 
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2.7 Mammosphere assay  
Mammosphere assays were performed according to Dontu G et al (92). 
MDA-MB-231 cells were freshly seeded and stimulated with Roscovitine at indicated concentrations 
for 24 h. The cells were washed with PBS and detached by trypsin/EDTA and collected by 
centrifugation. Cell pellets were resuspended in mammosphere culture medium at 40,000 cells/ml. 1 
ml of cell suspension was added to a poly-HEMA coated 12-well plate and cells were allowed to 
form mammospheres for 10 days. In the case of Roscovitine repeated treatment, Roscovitine was 
added every second day. In the case of nt/Cdk5 shRNA clones, the cells were freshly seeded in the 
same density in mammosphere medium containing puromycin. After treatment, mammospheres 
larger than 50μm were counted. Untreated cells (Co) or nt shRNA were set as 100%. 
 
Table 2.9 Mammosphere culture medium 
Content Amount 
MEGMTM Bullet Kit (Lonza)  500 ml 
EGF 20 ng/ml 
bFGF (human) 10 ng/ml 
Gibco® B-27® Supplements 50 ml 
Methylcellulose 1% 
Puromycin (for nt/Cdk5 shRNA clones) 1 μg/ml 
 
2.8 Western blotting 
2.8.1 Whole cell lysate preparation 
For Western blot analysis, cells were treated with desired substances as indicated.  
Cells were detached by trypsin/EDTA (for adherent cells) or directly collected by centrifugation and 
washed twice with ice-cold PBS, centrifuged, then appropriate amounts of lysis buffer were added. 
Samples were incubated on ice for 30 min and vortexed every 10 min. Lysates were centrifuged at 
14,000 rpm for 10 min. Supernatants were collected and transferred to a new tube. Protein 
concentrations were determined according to Bradford (93). Samples were diluted with 5x SDS 
sample buffer (4 parts lysate, 1 part buffer) and boiled for 5 min at 96℃. Samples were stored at -
20℃ until further analysis. 
Table 2.10 Buffers for the preparation of total cell lysates 
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Lysis buffer  Lysis buffer for phospho-proteins 
Tris-HCl, pH 7.5 30 mM  Tris-Base 20 mM
NaCl 150 mM  NaCl 137 mM
EDTA 2 mM  EDTA 2 mM
Triton X-100 1%  Triton X-100 1%
H2O Add 1,000 μl  C3H7Na2O6P 20 mM
CompleteTM 1:25  NaF 10 mM
  Na3VO7 2 mM
   Na4P2O7 2 mM
   PMSF 1 mM
   Glycerol 10%
   CompleteTM 1:25
 
 
5x SDS sample buffer 
Tris-HCl, pH6.8 3.125 M, 100 μl
Glycerol 500 μl
SDS 20% 250 μl
DTT 16% 125μl
Pyronin Y 5% 5 μl
H2O Add 1,000 μl
 
2.8.2 Protein quantification 
To employ equal amounts of protein for Western blot analysis, protein concentration was determined 
by Bradford assay (93). 10 μl protein samples were 1 : 10 diluted in water and mixed with 190 μl 
Bradford solution for 5 min. Afterwards, absorbance was measured at 592 nm using Tecan Sunrise™ 
Microplate reader. Serial diluted BSA samples were used as protein standards. Linear regression was 
used to calculate protein concentration from each sample.  
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2.8.3 Sample preparation 
 
After protein quantification, each sample was mixed with 5x SDS sample buffer as predescribed, and 
protein concentration was adjusted to the lowest concentration by adding 1x SDS sample buffer. 
Afterwards, the samples were boiled at 95℃ for 5 min. At this stage, the samples were kept at -20℃ 
or directly subjected to SDS-PAGE analysis. 
 
2.8.4 SDS-PAGE 
The SDS-PAGE gels were prepared in a discontinuous manner, with a stacking gel (Tris, pH 6.8) on 
top of the separation gel (Tris, pH 8.8). The concentrations of acrylamide in the separation gels were 
adjusted to optimize the separation of proteins according to their molecular weights. 
The Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, Germany) was used. Prior to 
sample loading, the apparatus was assembled according to manufacturer’s protocol and the chamber 
was filled with pre-cooled electrophoresis buffer.  
Before loading, samples were boiled at 95°C for 5 min. Equal amounts of protein (volume) from 
each sample were loaded on to the stacking gel.  
An equal volume of 1x SDS sample buffer containing 2 μl of prestained protein ladder PageRulerTM 
was loaded on each gel to estimate the molecular weights of the separated proteins. Electrophoresis 
was carried out at 100 V for 21 min for protein stacking and 200 V for 35-45 min for protein 
separation.  
 
 
Table 2.11 Acrylamide gels  
Stacking gel  Separation gel 12 % 
RotiphoreseTM Gel 30 1.7 ml  RotiphoreseTM Gel 30 6 ml
Tris-HCl 1.25M, (pH 6.8) 1 ml  Tris-HCl 1.25M, (pH 6.8) 3.75 ml
SDS 10% 100 μl  SDS 10% 150 μl
TEMED 20 μl  TEMED 15 μl
APS 10% 100 μl  APS 10% 75 μl
H2O 7.0 ml  H2O 5.1 ml
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Table 2.12 Electrophoresis buffer 
Electrophoresis buffer 
Tris 4.9 mM
Glycine 38 mM
SDS 0.1%
H2O 6.1 ml
 
2.8.5 Semi-dry blotting 
 
After protein separation, proteins on the gel were transferred onto a nitrocellulose membrane 
(Hybond ECLTM, Amersham Bioscience, Freiburg, Germany) by semi-dry blotting.  
The membrane was equilibrated with anode buffer 30 minutes before use. Blotting papers soaked in 
4℃ pre-cooled buffers were used to build the blotting sandwich in the Trans-Blot® SD Semi-Dry 
Electrophoretic Transfer Cell (Bio-Rad). Transfers were carried out at room temperature at 133 mA 
(for two gels) for 60 minutes. 
 
 
 
Figure 2.3 Assembly of semi-dry blot sandwich. Image was adapted from Bio-Rad, Trans-Blot® SD Semi-
Dry Assembly Guide. 
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Table 2.13 Semi-dry blotting buffers 
5x Tris-CAPS: 
Tris-Base 36.24 g 
CAPS (Amersham) 44.26 g 
H2O To 1000 ml
 
 
Anode buffer  Cathode buffer 
5x Tris-CAPS 20 ml  5x Tris-CAPS 20 ml 
Methanol 15 ml  10% SDS 1 ml 
H2O to 100 ml  H2O to 100 ml 
 
2.8.6 Protein detection 
After transferring proteins to the membrane, the gels were stained with comassie blue. Unspecific 
epitopes were blocked for 1 h (RT) with either 5% blotto or 5% BSA in PBS according to the 
requirements of different antibodies. Membranes were washed with 1x PBS-T and incubated with 
respective antibodies at 4℃ overnight. The next day, the membranes were washed three times for 10 
min with 1x PBS-T and then incubated in secondary antibodies for 2 h at room temperature.  
 
Table 2.14: Primary antibodies used for Western blotting analysis 
 
Antigen Source Dilution Provider 
β-actin Mouse monocl. 1:1000 Millipore 
Cdk5 human Mouse monocl. 1:1000 Invitrogen 
Cleaved Notch1 
(Val1744) (D3B8) 
Rabbit monocl. 1:1000 Cell Signaling Technology, Inc 
Notch1 (D1E11) XP® Rabbit monocl. 1:1000 Cell Signaling Technology, Inc 
Survivin Rabbit polycl. 1:1000 Cell Signaling Technology, Inc 
c-Myc (C-19) Rabbit polycl. 1:500 Santa Cruz Biotechnology 
β-tubulin Rabbit polycl. 1:1000 Cell Signaling Technology, Inc 
Antibodies were diluted according to manufacturer’s instructions. 
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Table 2.15 : Secondary antibodies used for Western blotting analysis 
Antibody Dilutions in Blotto 1% Provider 
HRP, Goat-Anti-Mouse IgG1 1:1000 Biozol 
HRP, Goat-Anti-Rabbit IgG (H+L) 1:1000 Bio-Rad 
 
2.8.7 Enhanced chemiluminescence (ECL) 
Proteins were detected by enhanced chemiluminescence (ECL) using horseradish peroxidase (HRP)-
conjugated secondary antibodies. After incubating with the secondary antibodies, the membranes 
were washed three times with PBS-T. Membranes were incubated with ECL PlusTM Western Blotting 
detection reagent (Amersham Bioscience) and chemiluminescence was detected by exposing an X-
ray film (Super RX, Fuji, Düsseldorf, Germany) for an appropriate period of time in the darkroom. 
Exposed X-ray films were then developed using Curix 60 developing system (Agfa-Gevaert AG, 
Cologne, Germany). 
2.8.8 Staining of gels and membranes  
Gels were stained for 30 minutes in the coomassie staining solution and destained with the Coomassie 
destaining solution (1h, RT) and with distilled water (ON, RT) to control equal loading of the gel 
and the performance of the transfer.  
 
Table 2.16 Gel staining solution  
Coomassi staining solution  Coomassi destaining solution 
Coomassie blue  3.0 g    Glacial acetic acid  100 ml
Glacial acetic acid  100 ml  Ethanol  333 ml
Ethanol  450 ml  H2O  ad 1,000 ml
H2O to 1,000 ml   
 
2.8.9 Gene expression profiling 
2.8.9.1  Preparation of cells 
Leukemia cells were suspended at 5×105 cells/ml, and 2 ml of the cell suspension was added into a 
6-well-plate. Archazolid A (10 nM) and DBZ (50 μM) were added to the cells. After 24 h of treatment, 
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the cells were collected and resuspended in 100 μl PBS, then 350 μl of RLT Buffer (with β-mercapto 
ethanol, QIAGEN, Hilden, Germany) were added. The samples were stored at -80℃ until further 
experiments were performed 
2.8.9.2  RNA isolation 
 
Total RNA was isolated using RNeasy kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s protocol. RNA was eluted in RNA-free water. RNA concentrations were measured 
with the NanoDrop® spectrophotometer (NanoDrop Technologies, Wilmington, Germany). 
 
2.8.9.3 Reverse transcription 
For the reverse transcription of RNA into cDNA, 3μg RNA from each sample were used and the 
reverse transcription reaction was performed using the High Capacity cDNA Revers Transcription 
Kit (Applied Biosystems, Foster City, CA, USA), which includes random primers. The reactions 
were taken out for 2 h at 37℃. cDNA was stored at 4℃ until qRT-PCR was performed. 
 
2.8.9.4 Semi-quantitive real-time PCR analysis 
For the quantitative real-time PCR the ABI 7300 Real-Time PCR system with the TaqMan Universal 
PCR Mastermix (Life Technologies Corporations, Carlsbad, CA, USA) was used. Probes and 
primers for the respective targets were supplied as mixture (Life Technologies Corporations, 
Carlsbad, CA, USA).  
Human primer of Notch downstream target HES1 (Life Technologies Corporation, Carlsbad, CA, 
USA) was used. 
As housekeeping gene, GAPDH was used (forward/reverse primer, probe sequence, biomers, Ulm, 
Germany). Fluorescence development was analyzed using the ABI 7300 system software. 
Calculation of relative mRNA was done according to Pfaffel (94). 
2.9 Transfection of cells  
2.9.1 Transfection of siRNA with Dharma FECT I 
250,000 MDA-MB-231 cells were seeded in 6 well-plates. After cell attachment, cells were 
transfected with the non-targeting (nt) siRNA or Cdk5 siRNA. To achieve optimal silencing effect, 
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two different ON-TARGET plus Cdk5 siRNA were equally used in a mixture (J-003239-09 and J-
003239-10; Thermo Scientific). A transfection mix per sample was prepared by mixing 5μM of 
siRNA in 10μl of sterile water with 190μl medium in tube A. Then 5μl of Dharma FECT I solution 
were diluted with 195μl medium in tube B. Five minutes later, the solution was mixed and left at RT 
for another 15min. Silencing of Cdk5 was achieved after 24 h. 
 
2.9.2 Cdk5 shRNA stable transduction in MDA-MB-231 cells  
Lentiviral transduction of MDA-MB-231 cells with Cdk5 shRNA and nt shRNA was performed by 
Bianca Hager (Ludwig-Maximilians-University, Munich, Germany) by means of MISSION® 
shRNA Lentiviral Transduction Particles (Sigma-Aldrich, Taufkirchen, Germany) according to the 
manufacturer´s protocol. Knockdown of Cdk5 was examined by Western blot analysis.  
 
2.10 Confocal microscopy 
2.10.1 Coating of coverslips for suspension cell staining 
2.10.1.1 Preparation of Chrome alum-gelatin coating solution 
 
Gelatin was dissolved in deionized H2O at 45℃. After the gelatin has dissolved, 0.5 g chromium 
potassium sulfate dodecahydrate (dissolved in 20 ml dH2O) was added. The solution was kept at 4℃ 
until use.  
Table 2.17 Chrome alum-gelatin coating solution 
Chrome alum-gelatin coating solution 
Gelatin (sigma) 4 g
CrK(SO4)2 · 12H2O 0.5 g
H2O to 1000 ml
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2.10.1.2 Coating of coverslips 
 
Gelatin solution was heated to 45℃ before use. Coverslips were submerged completely into the 
coating solution and then left drying for 2 days at room temperature. 
2.10.2 Immunostaining  
S-Jurkat cells were treated with Archazolid A (10 nM) and DBZ (50 μM) for 24 h, were then collected 
by centrifugation, resuspended in PBS, and seeded on chrome alum-gelatin coated coverslips and let 
adhere for 30 min at 37℃. Then the coverslips were individually put in each well of a 6-well plate. 
The samples were fixed in 4% PFA in PBS at room temperature for 10 min, washed with PBS for 
three times, permablized in PBS containing 0.2% Triton X-100 for 5 min, blocked with PBS 
containing 0.2% BSA for 1 h. Cells were then incubated with primary antibody in blocking solution 
for 1 h, RT. Before the secondary antibody was added, cells were washed three times with PBS 
before adding the secondary antibody for 1 h at RT. Cells were washed three times in PBS before 
mounting on a glass slide (Superfrost® Plus Micro Slide, VWR, Germany). 
For the LysoTracker® experiment, cells were collected after centrifugation, resuspended in PBS 
containing LysoTracker®. Cell suspension was then transferred to a ibidi μ-slide (8 well) and 
incubated at 37℃for a further 45 min. Hoechst 33342 was added and incubated at room temperature 
for 5 min in the dark. Then the samples were subjected to confocal microscopy. 
 
Table 2.18 Primary antibodies for immunostaining 
Antigen Source Dilution Provider 
Cleaved Notch1  
(Val1744) (D3B8) 
Rabbit monocl. 1:100 Cell Signaling Technology, Inc 
Notch1 (D1E11) XP® Rabbit monocl. 1:100 Cell Signaling Technology, Inc 
EEA1 (N-19) Goat polycl. 1:100 Santa Cruz Biotechnology 
LAMP1(H4A3) Mouse monocl. 1:200 Developmental Studies  
Hybridoma Bank 
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Table 2.19 Secondary antibodies for immunostaining 
Antibody Dilution Provider 
Alexa Fluor® 488 goat anti-rabbit IgG (H+L) 1:400 Molecular Probes® 
Alexa Fluor® 546 goat anti-mouse IgG (H+L) 1:400 Molecular Probes® 
Alexa Fluor® 546 donkey anti-goat IgG (H+L) 1:400 Molecular Probes® 
Alexa Fluor® 647 chicken anti-rabbit IgG (H+L) 1:400 Molecular Probes® 
 
2.11 Statistic evaluation 
 
All experiments were conducted at least three times in duplicates/triplicates. Results are expressed 
as mean value ± SEM. One-way ANOVA/Turkey and individual students t tests were conducted 
using Graph Pad Prism (version 5.04, GraphPad Software, Inc.). P values less than 0.05 were 
considered as significant. 
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3.1 Archazolid A inhibits V-ATPase activity in leukemia cells 
To confirm that Archazolid A inhibits V-ATPase activity in leukemia cells, we monitored endo-
lysosomal pH by LysoTracker® staining (Figure 3.1). 
In non-stimulated cells (Figure 3.1 Co), the pH sensitive Lysotracker accumulated in acidic 
organelles (such as endosomes and lysosomes), indicating intraorganellar acidification by active V-
ATPase. After Archaolizd A (10 nM, 24 h) treatment, endo-lysosomal acidification was reduced, as 
indicated by marked reduction in Lysotracker fluorescence intensity. As expected, treatment with the 
γ-secretase inhibitor Dibenzazepine (DBZ 50 μM, 24 h) did not alter V-ATPase activity. These 
results indicate that Archazolid A inhibits V-ATPase activity in leukemia cells. 
 
 
 
Figure 3.1: Archazolid A inhibits V-ATPase activity in S-Jurkat cells. 
S-Jurkat cells were either left untreated or treated with Archazolid A (10 nM) or DBZ (50 μM) for 24 h. V-
ATPase activity is monitored by pH sensitive dye LysoTracker® (red) staining. Nuclei are stained with Hoechst 
33342 (blue). Scale bar 20 μm. 
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3.2 Functional effects of Archazolid A and DBZ on leukemia cells 
To compare the effects of Archazolid A and γ-secretase inhibitor Dibenzazepine (DBZ) on two 
leukemia cell lines that were previously described to resist GSI treatment, we applied various 
functional assays.  
 
3.2.1 Archazolid A and DBZ inhibit leukemia cell proliferation 
 
Initially, to test the sensitivity of leukemia cells to Archazolid A and DBZ, a proliferation assay was 
performed, in which the cells were treated with various concentrations of these two substances for 
72 h. As shown in Figure 3.2 upper panel, Archazolid A inhibited proliferation of S-Jurkat and CEM 
cells at nanomolar concentrations (EC50 Jurkat 0.56 nM and EC50 CEM 0.51 nM), whereas DBZ 
showed anti-proliferative effects with lower potency at micromolar concentrations (EC50 Jurkat 15.5 
μM and EC50 CEM 12.7μM) (Figure 3.2 lower panel). 
 
 
 
Figure 3.2: Archazolid A and DBZ inhibit leukemia cells proliferation in a dose-dependent manner. 
Leukemia cell proliferation with Archazolid A and DBZ at indicated concentrations are shown (n=3, mean ± 
SEM). EC50 values were calculated with Graph Pad Prism. 
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3.2.2 Archazolid A and DBZ inhibit leukemia cell colony formation 
 
Various cancers including leukemia can acquire therapy resistance, meaning that some cells are able 
to recover upon short-time treatment. To analyze whether the leukemia cells were able to recover 
from treatment with Archazolid A and DBZ, a colony formation assay was performed. As shown in 
Figure 3.3 short-time treatment with Archazolid A for 24 h was able to dose-dependently decrease 
long-term colony formation in both leukemia cell lines. DBZ reduced colony formation as well, but 
with lower potency. 
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Figure 3.3: Archazolid A and DBZ inhibit leukemia cells colony formation. 
(A,B) Colony formation of leukemia cells treated with Archazolid A and DBZ for 24 h and freshly seeded for 
11 days are shown. Scale bar 100 μm. (C) Evaluation of colony formation in leukemia cells with indicated 
substances and concentrations is displayed. (n=3, mean ± SEM. One-way ANOVA, Tukey’s post-test, 
comparing to respective control *p<0.05,**p<0.01, ***p<0.001). 
3.2.3 The effects of Archazolid A and DBZ on apoptosis and cell cycle in leukemia cells 
In order to clarify the mechanism by which Archazolid A and DBZ inhibit leukemia cell growth, we 
stained cell with PI and performed apoptosis assay and cell cycle analysis.  
The apoptosis rate of leukemia cell lines treated with Archazolid A and DBZ at indicated time and 
doses are shown in Figure 3.3. Archazolid A treatment induced apoptosis time- and dose-dependently 
in both tested leukemia cell lines, whereas DBZ treatment showed no effect. 
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Figure 3.4: Archazolid A dose- and time- dependently induced apoptosis in leukemia cells. 
(A-C) Apoptosis rate of S-Jurkat and CEM cells at indicated times and after treatment with indicated 
concentrations of Archazolid A and DBZ are shown. Bars represent mean ± SEM. (C) n=3, one-way ANOVA, 
Tukey’s post-test, ***p<0.001. 
 
The inhibition of V-ATPase has been shown to induce apoptosis as well as cell cycle arrest in tumor 
cells (50, 95-97). Thus, we investigated the effects of Archazolid A and DBZ on cell cycle in 
leukemic cells. As shown in Figure 3.5, Archazolid A treatment induced G2-phase arrest in S-Jurkat 
cells (Figure 3.5 A), but had no influence on cell cycle in CEM cells (Figure 3.5 C ). DBZ had no 
effect on both cell lines (Figure 3.5 B, D). 
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Figure 3.5: Archazolid A induces G2-phase arrest in S-Jurkat cells. 
(A-D) Cell cycle analysis for S-Jurkat and CEM cells after 72 h of treatment with Archazolid A and DBZ at 
indicated concentrations is shown (n=3). (A) Archazolid A induced G2-phase arrest in S-Jurkat cells (n=3, 
student t-test, comparing to control **p<0.01,***p<0.001), but had no influence on CEM cells (C). (B,D) DBZ 
had no effects on cell cycle in both tested cell lines.  
 
3.3  Effects of Archazolid A and DBZ on Notch signaling in leukemia 
cells 
To investigate the effect of Archazolid A and DBZ on Notch signaling, we first tested the expression 
of Notch downstream target HES1 after treatment with Archazolid A and DBZ. As shown in Figure 
3.6, HES1 expression was reduced by both Archazolid A and DBZ. 
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Figure 3.6 Archazolid A and DBZ reduce Notch downstream target HES1. 
Relative expression level of HES1 in S-Jurkat cells after Archazolid A (10 nM) and DBZ (50 μM) 
treatment are shown. n=3, one-way ANOVA, Tukey’s post-test, **p<0.01, ***p<0.001. 
 
Furthermore, we analyzed whether Archazolid A affects Notch intracellular domain (NICD), which 
represents the active cleaved form of Notch receptor and is an indicator for Notch signaling activity. 
As it is revealed in Figure 3.7, Archazolid A treatment decreased NICD and, as expected, DBZ 
reduced NICD level as well. Furthermore, the Notch downstream target c-Myc was reduced by V-
ATPase inhibition with Archazolid A. DBZ also reduced c-Myc, but to a less extent, as it was 
previously described to contribute to GSI resistance of leukemic cells. Interestingly, in contrast to 
DBZ, V-ATPase inhibition by Archazolid A increased the level of Notch1 full-length receptor. 
Because Archazolid A induced apoptosis in leukemia cells, whereas DBZ had no effect. We further 
investigated whether the anti-apoptotic protein survivin was affected. In consistence with apoptosis 
induction, survivin level was decreased upon Archazolid A treatment, while it was unaffected by 
DBZ.  
 
 
 
Figure 3.7: Archazolid A and DBZ inhibits Notch signaling. 
Immunoblots from S-Jurkat cells treated with Archazolid A (left panel) or DBZ (right panel) and blotted with 
antibody against Notch1 (full length), NICD (Val1714),c-Myc and survivin are presented. Immunoblots for β-
tubulin are shown as loading control. n=3 
 
 
To further investigate the mechanism by which Archazolid A and DBZ impaired Notch signaling, 
we performed immunostainings. In line with the results from immunoblots, NICD was decreased 
upon treatment with Archazolid A as well as DBZ (Figure 3.8, upper panel). 
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Figure 3.8: Archazolid A and DBZ reduce NICD level. 
Immunostaining for NICD (green, upper panel) from S-Jurkat cells treated with Archazolid A and DBZ are 
shown. Nuclei are stained with Hoechest 33342 and displayed (blue, merged with NICD, lower panel). Scale 
bar 20 μm. 
 
Since impaired acidification of the endo-lysosomal compartment by V-ATPase inhibition might 
influence the activity of γ-secretase, and therefore reduce Notch receptor cleavage and leading to 
reduced NICD, we analyzed Notch1 receptor expression together with endosomal and lysosomal 
marker EEA1 and LAMP1. As shown in Figure 3.9, Archazolid A treated cells showed accumulation 
of Notch1 receptors in the endo-lysosomal compartments (Figure 3.9, green channel). These results 
showed that Notch1 receptors are trapped in the endo-lysosomal compartment. This indicates that 
Archazolid A treatment inhibited Notch1 cleavage at endo-lysosomal membranes. 
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Figure 3.9: Archazolid A induces accumulation of Notch1 receptor in the endo-lysosomal compartments. 
DBZ trapped Notch1 receptor on the cell surface. S-Jurkat cells were either treated with Archazolid A (10 
nM) or DBZ (50 μM) for 24 h, and cells were immonostained with endosomal marker EEA1 (A, red) or 
lysosomal marker LAMP1 (B, red) together with Notch1 (green). Hoechest 33342 staining was used to 
visualize nuclei. n=3, Scale bar 20 μm. 
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3.4 Archazolid A induced death of patient leukemic cells 
Finally, in collaboration with Prof. Dr. Jeremias and Dr. Grunert (Helmholtz Center of Munich) we 
studied the effect of Archazolid A on human primary leukemic cells. As in vitro cultivation of these 
cells is limited, cells were passaged in vivo by using immunocompromised mice (98). Upon isolation, 
primary ALL samples from five patients were stimulated with either Archazolid A or DBZ for 48 h. 
In consistance with cell culture experiments, whereas DBZ showed no effect, Archazolid A induced 
cell death in all tested patient samples (Figure 3.10). This indicated a therapeutic relevance of V-
ATPase inhibition by Archazolid A. 
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Figure 3.10: Archazolid A strongly induced cell death in primary human leukemic cells. 
(A) Dot plots (upper panel) and histograms (lower panel) from patient cells (Patient No.1) treated as indicated 
(48 h) are shown as example. In dot plots (upper panel), dashed ellipses show dead cells, solid ellipses 
show live cells. In histograms (lower panel), cells on the right side show high PI-signal and represent dead 
cells; while cells on the left side show low PI-signal and represent live cells. (B) Evaluations of cell death 
(%) from each patient samples treated with either Archazolid A or DBZ at indicated concentrations for 48 
h are shown, bars represent mean ± SEM. of each sample in duplicates. 
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4.1 Cdk5 inhibition exerts anti-tumor and anti-metastatic effects in 
metastatic breast cancer cells 
 
To analyze potential effects of Cdk5 inhibition by Roscovitine on breast cancer, we applied various 
functional assays by using MDA-MB-231 cells, highly metastatic and proliferating mesenchymal 
breast cancer cells. 
4.1.1 Roscovitine inhibits breast cancer cell proliferation  
Initially, we examined the effect of Cdk5 inhibition by Roscovitine on proliferation of MDA-MB-
231 cells. Roscovitine inhibited proliferation of MDA-MB-231 cells at micromolar concentrations 
with EC50 value of 13.7 μM (Figure 4.1). 
 
Figure 4.1: Roscovitine inhibits proliferation of MDA-MB-231 cells at micromolar concentrations. The 
bar graph displays inhibition of proliferation of MDA-MB-231 by Roscovitine. EC50=13.7 µM. (n=3). 
4.1.2 Effects of Cdk5 inhibition by Roscovitine on apoptosis and cell cycle 
In order to clarify the mechanism by which Roscovitine inhibits cell growth, we analyzed apoptosis 
and cell cycle transitions by Nicoletti assays. Treatment of proliferating MDA-MB-231 cells with 
increasing concentrations of Roscovitine induced apoptosis. Roscovitine caused a significant 
increase of apoptosis at 30 μM (Figure 4.2 A). Moreover, Roscovitine induced G2-phase arrest in 
MDA-MB-231 cells. 
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Figure 4.2: Roscovitine induced apoptosis and G2 cell cycle arrest in MDA-MB-231 cells. Proliferating 
MDA-MB-231 cells were either left untreated or treated with increasing concentrations of Roscovitine for 48 
h. (A) Apoptosis was determined according to the Nicoletti method. (One-way ANOVA, Tukey’s post-
test,***p<0.001). (B) Cell cycle analysis of proliferating MDA-MB-231 cells treated with Roscovitine at 
indicated concentrations is displayed. (n=3, student t-test, *p<0.05,**p<0.001). 
 
4.1.3 Roscovitine inhibits colony formation of breast cancer cells. 
Chemoresistant and metastatic tumor cells characteristically don’t get apoptotic upon short pulse of 
treatment and some cells are able to recover. To elucidate the effect of Roscovitine on long term 
survival and ability of cells to clonogenically expand, a colony formation assay was performed. As 
shown in Figure 4.3, Roscovitine reduced colony formation in a dose-dependent manner. 
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Figure 4.3: Roscovitine reduces colony formation in MDA-MB-231 cells.  
(A) Colonies formed from MDA-MB-231 cells treated with Roscovitine at indicated concentrations for 24 h 
and subsequently freshly seeded at low density and cultivated for further 7 days before staining with crystal 
violet are displayed. (B) Quantification of colony formation by absorbance measurement is shown. Bars 
represent mean ± SEM of three independent experiments performed in triplicates. (One-way ANOVA, Tukey’s 
post-test, ***p<0.001) 
 
4.1.4 Roscovitine inhibits migration of breast cancer cells 
To elucidate the effect of Roscovitine on the migration of metastatic breast cancer cells, transwell 
migration assays were performed, where cells have to migrate through a porous membrane.  
As shown in Figure 4.4, Roscovitine reduced transwell migration of MDA-MB-231 cells. 
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Figure 4.4: Roscovitine inhibits transwell migration of MDA-MB-231 cells.  
(A) Migrated MDA-MB-231 cells after pre-treatment before migration for 16 h are shown. Negative control (-
Co) and positive control (+Co) refers to absence or presence of FCS in the lower compartment. (B) Quantitative 
evaluation of transwell migration assays is shown. Bars represent mean± S.E.M. (n=3, One-way ANOVA, 
Tukey’s post-test, ***p<0.001). 
4.1.5 Cdk5 inhibition by Roscovitine reduced mammosphere formation. 
Cancer stem cells (CSCs) are able give rise to the whole cancer population, show high metastatic 
potential and can be responsible for treatment resistance. Potential effects of Cdk5 inhibition on 
CSCs were analyzed by mammosphere formation assays. In mammosphere assays, mammary 
epithelial cells are cultivated in non-adherent (anchorage-independent), low-nutrient (no-serum) 
environment, where only CSCs are able to clonally expand and form discrete spheroid-like structures 
called mammopsheres.  
 
As shown in Figure 4.5, Roscovitine inhibited mammopshere formation when applied at repeated 
doses as well as at a single dose.  
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Figure 4.5: Roscovitine reduced mammosphere formation. 
(A,C) Mammosphere formation after pretreatment of MDA-MB-231 cells with Roscovitine for 24 h before 
resuspension in fresh mammosphere medium and cultivation for further 10 days in the absence of Roscovitine 
(single dose) or continuous presence of Roscovitine (repeated dose) is shown. Scale bar: 100 μm. (B, D) 
Quantitative evaluation of numbers of mammospheres are shown. Bars represent mean ± SEM. (n=3, One-way 
ANOVA, Tukey’s post-test,*p<0.05, ***p<0.001). 
 
4.1.6 Silencing of Cdk5 inhibits breast cancer cells proliferation 
Roscovitine does not selectively inhibit Cdk5, but also Cdk1, Cdk2, Cdk7, and Cdk9 (88, 99). 
Therefore, we aimed to proof that Cdk5 is the relevant target of Roscovitine in breast cancer. Cdk5 
was genetically downregulated by RNA interference, using siRNA for transient silencing and 
lentiviral transduction of shRNA for stable knockdown. First, we analyzed the impact of Cdk5 
knockdown on proliferation of MDA-MB-231 cells.  
 
MDA-MB-231 cells were stably transduced with lentiviral vector expressing Cdk5 short hairpin 
RNA (shRNA). Cells that express non-targeting shRNA were used as control. Cdk5 shRNA breast 
cancer cells showed reduced proliferation (Figure 4.6 A), as compared to the non-targeting control 
(nt shRNA).  
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Figure 4.6: Cdk5 silencing inhibits breast cancer cell proliferation. 
(A) Proliferation of MDA-MB-231 cells transduced with non-targeting (nt) or Cdk5 shRNA is shown. (n=3, 
unpaired t-test, ****p<0.0001.). (B) Immunoblot for Cdk5 shows Cdk5 downregulation. β-actin was used as 
loading control. 
 
4.1.7 Cdk5 downregulation does not affect apoptosis or cell cycle transitions 
To test whether cdk5 is involved in the induction of apoptosis and cell cycle regulation in MDA-
MB-231 cells, we transiently silenced Cdk5 by siRNA and analyzed apoptosis and cell cycle 
transitions by Nicoletti assay. As shown in Figure 4.7, Cdk5 silencing did not affect apoptosis or cell 
cycle. 
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Figure 4.7: Silencing of Cdk5 has no effect on apoptosis induction and cell cycle. 
(A) Apoptosis assay and (B) cell cycle analysis in MDA-MB-231 cells transiently transfected with non-
targeting (nt) or Cdk5 siRNA. Bars represent mean ± SEM. (n=3) (C) Immunoblot shows Cdk5 silencing. 
 
4.1.8 Silencing of Cdk5 inhibits breast cancer cell colony formation 
Moreover, we analyzed colony formation of nt and Cdk5 shRNA MDA-MB-231 cells. Indeed, 
downregulation of Cdk5 reduced colony formation (Figure 4.8). 
 
 
 
Figure 4.8: Knockdown of Cdk5 inhibits colony formation in MDA-MB-231 cells. (A) Colony formation 
of nt and Cdk5 shRNA MDA-MB-231 cells is shown. One representative experiment out of three independent 
experiments is shown. (B) Quantitative evaluation of colony formation assays is shown. Bars represent mean± 
S.E.M (n=3, paired t-test, ****p<0.0001). (C) Immunoblot shows Cdk5 downregulation. Actin indicates equal 
loading. 
 
4.1.9 Silencing of Cdk5 inhibits breast cancer cells transwell migration and invasion 
In addition, we evaluated the effect of Cdk5 silencing in transwell migration assays. As shown in 
Figure 4.9, the migration of cells towards FCS was markedly decreased by Cdk5 siRNA.  
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Figure 4.9: Cdk5 silencing reduces MDA-MB-231 cells transwell migration. 
(A) FCS-induced migration of nt or Cdk5 siRNA treated MDA-MB-231 cells is shown. One representative 
experiment out of three independent experiments is shown. (B) Quantitative evaluation of transwell migration 
assays is shown. Bars represent mean± S.E.M (one-way ANOVA, Tukey’s post test,***p<0.001). C) 
Immunoblot shows Cdk5 silencing. Actin was used as loading control. 
 
In addition to migration, during metastasis cancer cells need to interact with the extracellular matrix. 
In order to analyze whether Cdk5 influences cancer cell invasion, we used a modified transwell 
migration model and coated the porous membrane with Matrigel®, an artificial extracellular matrix. 
As shown in Figure 4.10, both transient and stable knockdown of Cdk5 reduced MDA-MB-231 
invasion. Thus, Cdk5 was important for migration and invasion of MDA-MB-231 cells. 
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Figure 4.10: Cdk5 knockdown reduced MDA-MB-231 cells invasion. 
(A) FCS-induced invasion of MDA-MB-231 cells treated with nt or Cdk5 siRNA is shown. (B) Quantitative 
evaluation of nt or Cdk5 siRNA treated cells migrated through Matrigel®-coated membranes is shown. (n=3, 
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one-way ANOVA, Tukey’s post-test, ***p<0.001) (C) Immunoblot shows Cdk5 silencing. Actin indicates 
equal loading. (D) FCS-induced invasion of nt and Cdk5 shRNA MDA-MB-231 cells is shown. (E) 
Quantitative evaluation of nt or Cdk5 shRNA MDA-MB-231 cells migrated through Matrigel®-coated 
membranes is shown. Bars represents mean ± SEM. (n=3, one-way ANOVA, ***p<0.001, Tukey’s post-test). 
(C,F) Immunoblot shows Cdk5 knockdown. Actin indicates equal loading.  
 
4.1.10 Silencing of Cdk5 inhibits mammosphere formation 
Next, we aimed to determine whether the impaired mammopshere formation by Roscovitine was due 
to Cdk5 inhibition. As shown in Figure 4.11, Cdk5 downregulation led to reduced mammosphere 
formation down to approximately 60%. This suggests that Cdk5 was important for mammosphere 
formation in MDA-MB-231 cells. 
 
 
Figure 4.11: Cdk5 downregulation reduced breast cancer cell mammosphere formation. 
(A) Mammosphere formation of nt and Cdk5 shRNA MDA-MB-231 cells is shown. Scale bar : 100 μm. (B) 
Quantitative evaluation of mammosphere formation assays. n=3, paired t-test, *p<0.05. (C) Immunoblot shows 
Cdk5 downregulation. Actin indicates equal loading.
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5.1 Evaluation of the V-ATPase inhibitor Archazolid for treatment of T-
cell acute lymphoblastic leukemia 
This study demonstrates that V-ATPase inhibition by Archazolid A induces apoptosis of leukemic 
cells that are resistant to γ-secretase inhibitor treatment. Archazolid A inhibits Notch signaling in a 
different mode of action than GSIs, i.e. by blocking endosomal Notch processing due to V-ATPase 
inhibition, and abrogates the pro-survival protein survivin. Thus, we suggest V-ATPase as a potential 
drug target for T-ALL and V-ATPase inhibition by Archazolid A as an alternative therapeutic option 
for T-ALL. 
 
5.1.1 GSI treatment in T-ALL 
Studies showing that more than 50% of T-ALL cases have Notch activating mutations have broaden 
our understanding for T-ALL origin and have highlighted Notch inhibition as a therapeutic strategy 
(2). Given the strict requirement of γ-secretase for Notch signaling activation, Notch inhibition via 
GSI seems to be a promising approach to treat T-ALL. Therefore, GSIs have been evaluated in 
clinical trials for T-ALL therapy. However, in clinical trials, GSI treatment was unsuccessful in T-
ALL treatment. GSI treatment exerted only moderate cytostatic effects and failed to induce apoptosis 
in various leukemic cell lines (2, 5), resulting in only weak anti-leukemic effects and poor clinical 
response (1). In fact, GSI treatment is only effective when the cells express membrane-bound Notch 
receptors that require γ-secretase processing. In Notch activation mutant T-ALL cells, such as those 
lack PEST domain (required for ubiquitination, followed by proteosomal degradation), GSI will not 
have beneficial effects. In some T-ALL cell lines, GSIs failed to induce Notch down-regulations, 
because proteasomal Notch degradation was inhibited due to mutations of the Notch receptor that 
impaired Notch ubiquitination or the ubiquitin ligase FBW7 that is essential for Notch proteasomal 
degradation (100). In T-ALL cell lines that carry FBW7 mutations, such as Jurkat and CEM, the 
mutated FBW7 either cannot bind NICD or cannot target its downstream target c-Myc for 
degradation and therefore contributes to GSI resistance (100). 
Moreover, gastrointestinal toxicity was also observed in T-ALL patients with systemic GSI treatment. 
Nowadays, no drugs that block Notch activation have entered the clinic and the treatment of T-ALL 
remains a problem due to high rate of relapse and resistance. 
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5.1.2  Archazolid A inhibits Notch signaling in a mode of action different from GSIs 
 
We suggest V-ATPase inhibition as alternative strategy to block Notch signaling in leukemic cells. 
We show that V-ATPase inhibition by Archazolid A induces apoptosis in leukemic cell lines that do 
not get apoptotic by GSI treatment and suggest an alternative mode of action: blocking of Notch 
activation by inhibition of its endosomal processing. Notch receptor internalization/endocytosis after 
ligand binding is important for Notch signaling activation (101). Low pH is a prerequisite for γ-
secretase mediated Notch signaling activation in the endo-/lysosomal compartment (102). V-ATPase 
is required for activation of the Notch receptor by regulating its endosomal cleavage via γ-secretase 
(53, 54). In Drosophila, mutations of V-ATPase lead to defects in processing of the internalized 
Notch receptor. By V-ATPase inhibition, the Notch receptor is trapped in the endo-lysosomal 
compartment but cannot get cleaved and activated (53, 54). Kobia et al showed V-ATPase inhibition 
by Bafilomycin A1 (BafA1) reduced Notch signaling during drosophila and zebrafish development 
and in human cells. BafA1 treatment led to Notch accumulation in the endo-lysosomal system and 
inhibited growth of Notch-dependent breast cancer cells. In contrast, BafA1 treatment reduced 
leukemia cell growth without affecting Notch signaling activation. Our results demonstrate that V-
ATPase inhibition by Archazolid A induced apoptosis of leukemic cells in contrast to GSI. Although 
both Archazolid A and DBZ reduced Notch signaling activity, our results demonstrate that V-ATPase 
inhibition exerted an alternative mode of action. Like DBZ, Archazolid A reduced Notch receptor 
cleavage at S3-site (Val1744). However, in contrast to GSI treatment, by Archazolid A treatment, 
the Notch receptor accumulated in the endo-lysosomal compartment but not at the cell surface. 
Moreover, Archazolid A reduced levels of c-Myc, a crucial transcriptional target of Notch1 (6, 103-
105), more efficiently than DBZ. In addition, the anti-apoptotic protein survivin was reduced by 
Archazolid A but not by DBZ. Thus, reduction of c-Myc and survivin by Archaozlid A could be 
another and/or an additional mechanism that triggers cell death in leukemia cells (100, 106).  
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Figure 5.1 Functional V-ATPase is required for Notch signaling activation 
Under normal conditions, V-ATPase pumps protons into the endo-lysosomal lumen in an ATP-dependent 
manner. Acidic environment is essential for optimal Notch1 receptor cleavage by γ-secretase, releasing NICD 
from plasma membrane, which then translocates to the nucleus and subsequently activates Notch signaling. V-
ATPase inhibition by Archazolid A impaired endo-lysosomal acidification, and therefore inhibited endo-
lysosomal Notch1 receptor cleavage by γ-secretase, leading to reduced Notch signaling. 
 
Survivin is a member of the inhibitor of apoptosis protein (IAP) family, that is involved in many 
pathways regulating cellular homeostasis (107). Survivin negatively regulates apoptosis by inhibiting 
caspase activation. Survivin is shown to be overexpressed in more than 90% of adult T-cell leukemia 
and in T-ALL cell lines. Increased survivin level is linked to poor clinical outcomes (108, 109) and 
mediates drug resistance. Targeting survivin using antisense oligonucleotides in combination with 
chemotherapy was indicated to eliminate relapsed T-ALL in a xenograft model (110). A link between 
Notch1 and survivin has already been indicated, i.e. Notch1 regulates the expression of survivin 
through NF-κB. In breast cancer Notch1 triggered NF-κB signaling pathway activation and 
upregulated the expression of survivin (111). Moreover, downregulation of Notch1 reduced NF-κB 
activity and pharmacological inhibition NF-κB could suppress the expression of survivin (112, 113). 
Our results show that V-ATPase inhibiton via Archazolid A decreased survivin whereas DBZ had 
no effect. This might indicate that the effect of Archazolid A on apoptosis induction does not 
exclusively depend on inhibition of Notch1, but is mediated at least in part by decreased survivin. A 
5 Discussion 63
previous study in cadiomyocytes showed V-ATPase inhibition via Bafilomycin A1 enhanced 
expression of p53 (114). Because survivin is negatively regulated by p53 and participates in p53-
dependent apoptotic pathway (115), V-ATPase inhibition might up-regulate p53, suppressing 
survivin and inducing apoptosis in leukemic cells. 
 
5.1.3 Conclusions 
In summary, our results demonstrate that V-ATPase inhibition by Archazolid A exerts anti-leukemic 
properties. Archazolid A induces leukemic cell death by inhibition of Notch signaling activation in 
a way different from γ-secretase inhibitors (GSIs), and by decreasing the anti-apoptotic protein 
survivin. Therefore, we suggest V-ATPase is an attractive target for T-ALL therapy and V-ATPase 
inhibition by Archazolid A as an alternative strategy for treating leukemic cells that are resistant to 
γ-secretase inhibitor treatment. 
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5.2 Evaluation of Cdk5 as target for breast cancer treatment 
Our study indicates an important role of Cdk5 in breast cancer growth and motility and indicates a 
function of Cdk5 in breast cancer stem cells (CSCs). Therefore, Cdk5 might represent a novel 
drugable target for breast cancer treatment. 
 
5.2.1 Cdk5 is crucial for breast cancer progression 
 
Cdk5 is a serine/threonine kinase that exerts important functions in the central nervous system (83). 
In contrast, only recently, the awareness of non-neuronal functions of Cdk5 has grown and its role 
in cancer is not well investigated. Recently, few reports indicated functions of Cdk5 in cancer (116-
119). In pancreatic cancer, Cdk5 expression was amplified and increased metastasis via Ras-Ral 
signaling and mutant K-Ras (116, 117). In prostate cancer, Cdk5 regulates cell motility and 
metastatic potential (118). In non-small cell lung cancer (NSCLC) a correlation of Cdk5/p35 
expression with poor prognosis of patients has been indicated (119). Furthermore, dysregulated high 
activity of Cdk5 in C cells of the thyroid gland was reported to initiate the formation of medullary 
thyroid carcinoma via phosphorylation of retinoblastoma protein (120). Recently, Cdk5 was linked 
to epithelial-mesenchymal transition (EMT) of breast epithelial cells (121). The authors 
demonstrated that Cdk5 is essential for TGF-β1 induced EMT in normal breast epithelial cells (121). 
EMT is a process that can lead to CSC formation. During EMT, epithelial cells lose their polarity, 
cell-cell-adhesion and gain migratory and invasive properties to become mesenchymal (stem) cells 
(122). The relatively high rate of relapse of aggressive breast cancer is attributed to breast cancer 
stem cells (CSCs) (122). Breast CSCs are resistant to standard therapy, show high tumor-initiating 
potential and cause establishment of metastases (122). Therapeutic strategies that target breast CSCs 
therefore may substantially improve breast cancer treatment and patient prognosis. 
Our present work indicates a function of Cdk5 in breast CSCs. In line with a recent study we 
elucidated essential functions of Cdk5 in breast cancer cell proliferation and metastasis (121). Above 
that, our results suggest an implication of Cdk5 in breast CSC formation. Because genetic 
knockdown as well as pharmacologic inhibition of Cdk5 reduced mammosphere formation, we 
suggest Cdk5 as druggable target for inhibiting breast CSC formation.  
 
To pharmacologically inhibit Cdk5, we used Roscovitine, a well-established Cdk5 inhibitor. 
Roscovitine is one of the earliest found and well established Cdk inhibitors and it has already been 
tested in clinical trials (123). Roscovitine has been shown to induce apoptosis and cell cycle arrest in 
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many types of cancer (88, 124-127). Although Roscovitine is the most widely used Cdk5 inhibitor, 
its activity is not restricted to Cdk5. Besides Cdk5, other Cdks are inhibited by Roscovitine, including 
Cdk1, Cdk2, Cdk7, and Cdk9 (88, 99). Our results point to a potential function of other Cdks besides 
Cdk5 in breast cancer because, unlike Cdk5 silencing, Roscovitine inhibited cell cycle progression 
and induced apoptosis of breast cancer cells. Nevertheless, some studies indicated the involvement 
of Cdk5 in cell death of cervical and prostate cancer (124, 128, 129).  
 
Along this line, it would be interesting to analyze the effects of more specific Cdk5 inhibitors in 
breast cancer. Recent work aimed to develop new Cdk5 inhibitors with higher specificity and potency. 
Some of these inhibitors have been developed by using Roscovitine as mother substance and share 
the core structure of Roscovitine (130-133). Consequently these substances interact with the same 
ATP-binding pocket, possibly limiting their selectivity. Targeting the interaction of Cdk5 and its 
activators has been described as new approach to bypass the selectivity problem (134-136). Along 
this line, inhibiting the interaction of Cdk5 with its activator could represent a promising strategy for 
breast cancer therapy. However, it is not clear, how Cdk5 gets activated in breast cancer. Thus, 
further studies are required to better understand Cdk5 regulation in cancer. 
 
To elucidate downstream targets of Cdk5 in breast CSCs remains another interesting question.  
The forkhead box protein C2 (FoxC2), also called forkhead-related protein (FKHL14), has been 
associated with aggressive basal-like breast cancers and is implicated in breast cancer metastasis, 
EMT and CSC formation (137). Our recent study established a link between Cdk5 and FoxC2. Ivanov 
et al. showed that phosphorylation of FoxC2 regulates its transcriptional activity (138). Extending 
the knowledge about FoxC2 regulation, we showed that Cdk5 is the kinase responsible for FoxC2 
phosphorylation which is essential for lymphatic vessel development and valve formation (Nat. 
Commun., in revision). Along this line, FoxC2 might be regulated by Cdk5 in breast cancer cells as 
well, contributing to the effects of Cdk5 on CSC formation. First experiments (performed by Melanie 
Mandl) point to a link between Cdk5 and FoxC2 in breast CSCs: overexpression of Cdk5/p35 
together with FoxC2 increased mammosphere formation at higher extent than single overexpression 
of Cdk5/p35 respectively FoxC2. To elucidate whether Cdk5-mediated FoxC2 phosphorylation is 
implicated in breast CSCs, analysis of mammospheres after overexpression of a FoxC2 
phosphorylation mutant together with Cdk5 is needed. 
The Notch pathway represents another potential Cdk5 downstream target. The Notch pathway is 
critically involved in breast CSC formation and inhibition of Notch signaling can reduce 
mammosphere formation (139). We could recently show that Cdk5 controls tumor angiogenesis by 
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regulating the Notch pathway in the endothelium (manuscript in preparation). Therefore, the Notch 
pathway might be a possible downstream target of Cdk5 regulating CSCs. 
5.2.2 Conclusions  
 
In summary, our study established a crucial role of Cdk5 in breast cancer progression and breast CSC 
formation. Our study therefore suggests Cdk5 as a potential drugable target for breast cancer 
treatment. 
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6.1 Part 1: Evaluation of the V-ATPase inhibitor Archazolid for 
treatment of T-cell acute lymphoblastic leukemia 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy that is 
characterized by the infiltration of bone marrow with immature T-cells (1). T-ALL patients suffer 
from huge tumor burden, mediastinal enlargement and also have high a risk of CNS involvement (1). 
Nowadays, treatment intensification has improved T-ALL treatment. However, the treatment of T-
ALL remains a problem in the clinic due to resistance and relapse (1). Notch activating mutations 
contribute to T-ALL initiation and progression (2). γ-secretase inhibitors (GSIs) are used as 
therapeutics to inhibit Notch signaling in T-ALL. However, resistance to GSI emerged as major 
problem and GSIs failed in clinical trials due to moderate cytostatic and poor anti-leukemic property 
(1). In this study, we demonstrate that V-ATPase inhibition by Archazolid A exerts anti-proliferative 
effects, induces apoptosis, and inhibits clonogenic survial of T-ALL cell lines that a resistant to GSI 
treatment. Moreover, Archazolid A inhibits Notch signaling in a different mode of action than GSIs, 
i.e. by blocking endosomal Notch processing and by abrogating the pro-survival protein survivin. In 
summary, our results demonstrate that V-ATPase inhibition by Archazolid A exerts anti-leukemic 
properties. Therefore, we suggest V-ATPase is an attractive target for T-ALL therapy and V-ATPase 
inhibition by Archazolid A as an alternative strategy for treating leukemic cells that are resistant to 
γ-secretase inhibitor treatment. 
 
6.2 Part 2: Evaluation of Cdk5 as target for breast cancer treatment 
For many years, Cdk5 was thought to function exclusively in the central nervous system. However, 
there is an increasing number of studies that show its function in the periphery and some reports 
indicated functions of Cdk5 in cancer progression. Our present study elucidates an important role of 
Cdk5 in breast cancer, pointing to a function of Cdk5 in breast cancer stem cells (CSCs) and 
suggesting Cdk5 as a novel drugable target for breast cancer treatment. Tissue micro assay analysis 
from human patient samples showed elevated Cdk5 expression in breast cancer tissue. Genetic 
knockdown and pharmacologic inhibition of Cdk5 inhibited breast cancer cell proliferation and 
colony formation, and reduced cell motility and invasion. Recently, Cdk5 was linked to epithelial-
mesenchymal transition (EMT) of breast epithelial cells (121). EMT can induce formation breast 
CSCs that are resistant to common therapies, have high tumor initiating potential and cause tumor 
recurrence (64). In fact, genetic and pharmacologic inhibition of Cdk5 decreased mammosphere 
formation, indicating a function of Cdk5 in breast CSCs. In summary, our study elucidated a crucial 
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role of Cdk5 in breast cancer progression and breast CSC formation. Our study therefore suggests 
Cdk5 as a potential drugable target for breast cancer treatment. 
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8.1 Abbreviations  
 
Table 8.1 List of Abbrevations 
ANOVA Analysis of variance between groups 
APS Ammoniumpersulfate 
Arg Arginine 
ATP Adenosine triphosphate 
bFGF human basic fibroblast growth factor 
BSA Bovine serum albumin 
CAPS Cyclohexylamino-1-propane sulfonic acid 
Cdk Cyclin dependent kinase 
cDNA Complementary desoxyribonucleic acid 
CIP Cdk5 inhibitory peptide 
CNS Central Nervous System 
DBZ Dibenzazepine 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EC50 Half maximal effective concentration 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
FACS  Fluorescence activated cell sorter 
FCS  Fetal calf serum 
FL2-A Fluorescent channel 2 area 
FL2-H Fluorescent channel 2 height 
FS Fluorochrome solution 
FSC Forward scatter 
Glu Glutamic acid 
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h Hour 
hEGF Human epidermal growth factor  
HFS Hypotonic fluorescent solution 
HRP  Horseradish peroxidase 
LSM Laser scanning microscope 
mg, ml, mM Milligram, milliliter, millimolar 
min Minute(s) 
mRNA Messenger ribonucleic acid 
nM Nanomolar 
nm Nanometer 
nt siRNA Non targeting small interfering ribonucleic acid 
PBS Phosphate buffered saline 
PFA Paraformaldehyde 
PI Propidium iodide 
PMSF Phenylmethylsulfonyl fluoride 
Poly-HEMA Poly(2-hydroxyethyl methacrylate) 
RNA  Ribonucleic acid 
rpm Revolutions per minute 
RT Room temperature 
RT PCR Reverse transcriptase polymerase chain reaction 
SEM Standard error of the mean value 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
shRNA Short hairpin ribonucleic acid 
siRNA Small interfering ribonucleic acid 
T/E Trypsin/EDTA 
TACE TNF-α converting enzyme 
TEMED N, N, N’, N’ tetramethylethylene diamine 
TMA Tissue microarray 
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Tris Trishydroxymethylaminomethane 
μg, μl, μM Microgram, microliter, micromolar 
ANOVA Analysis of variance between groups 
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8.4 Manuscript “Cdk5 controls lymphatic vessel development and 
function by phosphorylation of FoxC2” 
Initially we were interested in the function of Cdk5 in the endothelium. We established endothelial 
cells-specific Cdk5 knockout mice and studied Cdk5 function in vivo. I participated in this project 
and performed a huge variety of experiments that contributed to the characterization of the 
phenotypes of the EC-Cdk5 knockout mice. 
Here, under Dr. Johanna Liebl’s permission, I attached the submitted manuscript for the paper “Cdk5 
controls lymphatic vessel development and function by phosphorylation of FoxC2” as appendix in 
my thesis. 
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Abstract28?
The lymphatic system maintains tissue fluid balance, and dysfunction of lymphatic vessels 29?
and valves causes human lymphedema syndromes. Yet, our knowledge on the molecular 30?
mechanisms of lymphatic vessel development is still limited. This study demonstrates Cdk5 31?
as essential regulator of lymphatic vessel development. Endothelial-specific Cdk5 32?
knockdown causes congenital lymphatic dysfunction and lymphedema due to defective 33?
lymphatic vessel patterning and valve formation. We identify Foxc2 as responsible Cdk5 34?
substrate in lymphatic vasculature, mechanistically linking Cdk5 to lymphatic development 35?
and valve morphogenesis. We present the Cdk5-Foxc2 interaction as critical regulator of36?
lymphatic vessel development and the transcriptional network underlying lymphatic vascular 37?
remodeling. 38?
 39?
 40?
Introduction41?
The lymphatic system maintains key physiological functions like tissue fluid homeostasis, 42?
immune surveillance, and uptake of dietary lipids. In consequence, the lymphatic vasculature 43?
plays a key role in various human pathologies. Lymphangiogenesis occurs in chronic 44?
inflammation and tumor dissemination, and dysfunction of lymphatic vessels causes human 45?
lymphedema syndromes 1. Yet, our knowledge about the mechanisms regulating lymphatic 46?
vessel development and function is still limited.  47?
Lymphatic vessel formation starts after the circulatory system has established. Lymphatic 48?
endothelial cells emerge from the cardinal veins and migrate away to form the primary 49?
lymphatic vessels, i.e. the lymph sacs, which get separated from the blood vasculature by 50?
lymphovenous valves 2-4. Peripheral lymphatic vessels remodel into lymphatic capillaries that 51?
take up interstitial fluid and collecting lymphatic vessels that drain the lymph into the venous 52?
system. Lymphatic capillaries are blind-ending and lack mural cells, whereas collecting 53?
lymphatic vessels contain smooth muscle cell (SMC) coverage and intraluminal valves 5. 54?
Several regulators of lymphatic vessel remodeling and valve formation have been identified, 55?
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?
including ephrinB2 6, integrin-?9 7, semaphorinA3 8,9, Prox1 4 and Foxc2 10. Yet, their 56?
molecular regulation in the lymphatic endothelium is largely unknown. 57?
Cyclin dependent kinase 5 (Cdk5), a proline-directed serine/threonine kinase, does not drive 58?
cell cycle transitions though it belongs to the Cdk family. Since it exerts essential functions in 59?
the central nervous system (CNS) such as neuronal migration, axonal guidance, and 60?
synaptic plasticity, and has been associated with neurodegenerative and neuropsychiatric 61?
diseases, Cdk5 was supposed to be neuron-specific for a long time 11.  62?
Recently, the awareness about extra-neuronal functions of Cdk5 has grown. Cdk5 was linked 63?
with inflammation, i.e. leukocyte activation, with obesity and insulin-resistance by 64?
phosphorylating the transcription factor PPAR?, and some reports indicate functions of Cdk5 65?
in cancer (reviewed in 12). In contrast, a detailed investigation of a possible function of Cdk5 66?
in the endothelium in vivo is still lacking. To address this issue, we generated two endothelial 67?
specific Cdk5 knockout models as a basis for mechanistic studies on the role of Cdk5 in the 68?
vascular system, including the search for the functionally relevant endothelial substrate of 69?
Cdk5. 70?
71?
72?
Results and Discussion 73?
74?
Phenotype of endothelial-specific Cdk5 knockout mice. 75?
Cdk5 and its activator p35 are ubiquitously expressed in the vasculature (Supplementary Fig. 76?
S1 and S3). We disrupted the Cdk5 gene specifically in mouse endothelium by using the 77?
Cre/loxP system with a constitutive Tie2Cre and a tamoxifen-inducible VE-Cadherin 78?
Cdh5(PAC)-CreERT2 transgene 13 (Supplementary Fig. S2 and S3). Loss of Cdk5 in the 79?
mouse endothelium resulted in postnatal lethality with more than 40% of mice dying during 80?
the first two days after birth or at the age of 3-4 weeks after weaning (Fig. 1a). Born 81?
Cdk5fl/flTie2Cre mice showed reduced size and body weight (Fig. 1b,c) and we observed 82?
frequent bleedings (Fig. 1d, Supplementary Fig. S2e). Instead of expected 25%, only 15% of 83?
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?
progeny had the Cdk5fl/flTie2Cre genotype (Fig. 1e), suggesting embryonic lethality. Indeed, 84?
endothelial-specific Cdk5 knockout embryos died from E16.5 onwards. They showed blood-85?
filled dilated tortuous vessels extending from the jugular region towards the abdominal area, 86?
bleedings especially prevalent in jugular regions and edema formation (Fig. 1f-h), indicating 87?
severe lymphatic vessel defects. Cdk5 protein levels were attenuated in lymphatic 88?
endothelial cells (LECs) and blood vessel endothelial cells (BECs) of Cdk5fl/flTie2Cre 89?
embryos (Fig. 1i). The Tie2 promoter is active both in endothelial cells and some 90?
hematopoietic cells such as monocytes or macrophages 14. In addition, functions of Cdk5 in 91?
the hematopoietic system have been reported, including an implication of Cdk5 in T-cell 92?
activation and experimental autoimmune encephalomyelitis 15 or an involvement of Cdk5 in 93?
hematopoietic cell differentiation 16-18. To confirm the role of Cdk5 in endothelial cells, we 94?
used a VE-Cadherin (VEC) Cre driver line, i.e. the tamoxifen-inducible Cdh5(PAC)-CreERT2 95?
line. Cdk5fl/flCdh5(PAC)-CreERT2 (Cdk5fl/flVECCre) embryos from tamoxifen-treated mothers 96?
show a highly similar phenotype as embryos with Cdk5fl/flTie2Cre genotype (Fig. 1f,g), 97?
demonstrating an endothelial cell autonomous function of Cdk5. To assess the effect of more 98?
prevalent loss of Cdk5 in the endothelium, we derived mice in which one Cdk5 allele was 99?
constitutively deleted (?) and the remaining allele was floxed (fl) (Fig. 1h,j). Indeed, embryos 100?
with Cdk5?/flTie2Cre genotype died at E15.5, with blood-filled dilated tortuous vessels, 101?
hemorrhaging and edema formation (Fig. 1h). Thus, more pronounced loss of Cdk5 resulted 102?
in more severe lymphatic deficiencies. In summary, the similarity of the phenotypes of 103?
endothelial Cdk5 knockdown mice achieved by different Cre driver lines indicates a specific 104?
and essential function of endothelial Cdk5 for lymphatic vessel development.  105?
106?
Knockdown of Cdk5 in the endothelium leads to lymphatic vessel dysfunction. 107?
EC-specific Cdk5 knockout embryos exhibited markedly dilated vessels that were of 108?
lymphatic origin as they expressed Lyve1, but contained blood cells, demonstrating a 109?
persisting connection between lymphatic and blood vessels (Fig. 2a and Supplementary Fig. 110?
S5a,b). Also the primary lymph sacs of Cdk5fl/flTie2Cre embryos were severely dilated and 111?
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filled with blood (Fig. 2b-d). Moreover, lymphatic capillaries displayed defective patterning. 112?
They were covered with ectopic SMCs, irregularly dilated and showed decreased branching 113?
(Fig. 2e-g). 114?
In contrast to the striking lymphatic vessel defects, blood vessel morphology of 115?
Cdk5fl/flTie2Cre embryos was not affected. EphrinB2 and EphB4 were expressed at 116?
comparable levels in arteries and veins of control and Cdk5fl/flTie2Cre embryos and SMC 117?
coverage of blood vessels was not changed (Supplementary Fig. S4). 118?
In consequence, our further studies focused on the lymphatic vessel phenotype of EC-119?
specific Cdk5 knockout mice. FITC-lectin or Evans Blue was intravenously injected to study 120?
the abnormal connection of blood and lymphatic systems. The dye exclusively stained blood 121?
vessels in control, but reached large collecting lymphatic vessels in Cdk5fl/flTie2Cre mice 122?
(Fig. 2h,i and Supplementary Fig. S5c). FITC-lectin or Evans blue dye did not stain 123?
subcutaneous tortuous lymphatic microvessels of Cdk5fl/flTie2Cre embryos (Supplementary 124?
Fig. S5d,e) indicating that the abnormal communication was not due to anastomosis between 125?
blood and lymphatic capillaries.  126?
The functionality of lymphatic vessels was further tested by subcutaneous injection of Evans 127?
blue at E16.5 or postnatally. The significantly impaired dye removal in Cdk5fl/flTie2Cre mice 128?
demonstrated a lymphatic drainage defect (Fig. 2j,k).  129?
 130?
Arrested lymphatic valve formation in endothelial-specific Cdk5 knockout mice. 131?
To understand the lymphatic drainage defect, we first analyzed EC apoptosis which was not 132?
affected in Cdk5fl/flTie2Cre embryos (Supplementary Fig. S6a-d). Intraluminal valves are 133?
crucial for lymphatic function and expressed Cdk5 (Fig. 3a). Stainings of skin and mesentery 134?
revealed reduced numbers of lymphatic valves and impaired lymphatic valve morphogenesis 135?
in EC-specific Cdk5 knockout embryos (Fig. 3b-j and Supplementary Fig. S7). The majority 136?
of lymphatic valve forming cells failed to reorient and form valve leaflets (Fig. 3g-j), which 137?
was especially prevalent in embryos with severe phenotypes. Moreover, quantification of 138?
Prox1 positive nuclei of lymphatic endothelial cells indicated hyperplasia of lymphatic vessels 139?
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in Cdk5fl/flTie2Cre embryos (Supplementary Fig. S6e-h). In addition, we analyzed whether the 140?
role of Cdk5 in lymphatic valve formation also encompasses lymphovenous valves, which 141?
separate the primordial thoracic duct (pTD) and adjacent cardinal vein (CV) 3,4,19,20. Three 142?
dimensional (3D) reconstructions of image stacks obtained by optical sectioning of entire 143?
wholemount immunostained E12.5 embryos showed lymphovenous valves, i.e. two contact 144?
sites of double layer of endothelial cells with high Prox1 expression, in control littermates and 145?
demonstrated frequent failure of lymphovenous valve formation in Cdk5fl/flTie2Cre embryos 146?
(Fig. 4). To understand whether Cdk5 is also essential for valve maintenance, we postnatally 147?
deleted endothelial Cdk5 in mature valves by using tamoxifen inducible Cdh5(PAC)-148?
CreERT2 mice. Lymphatic vessels and valves appeared normal in tamoxifen-treated 149?
Cdk5fl/flVECCre mice (Fig. 5a,b). In sum, our data demonstrate an indispensable endothelial 150?
cell autonomous requirement of Cdk5 for lymphatic vessel development and valve formation 151?
but not for valve maintenance. 152?
 153?
Cdk5 controls Foxc2 transcriptional activity by phosphorylation. 154?
Next, we aimed to understand Cdk5-driven signaling in the lymphatic vasculature. We 155?
analyzed expression of crucial LEC specific genes whose inactivation or mutation revealed 156?
lymphatic vessel phenotypes reminiscent to endothelial Cdk5 knockout embryos: the 157?
forkhead transcription factor Foxc2 10, the O-glycoprotein podoplanin 21,22, T-synthase (T-158?
Syn), i.e. a glycosyltransferase critical for the biosynthesis of O-glycans including podoplanin 159?
23, the homeobox transcription factor Prox1 4, Ets transcription factors Ets1 and Ets2 24. The 160?
transcription factors Ets1, Ets2, and Foxc2 are regulated by phosphorylation at 161?
serine/threonine residues 24,25 and therefore might be of special interest as potential Cdk5 162?
targets. However, we did not find obvious changes in expression of Foxc2, Prox1, Ets1 and 163?
Ets2, podoplanin, or VEGFR3 (Supplementary Fig. S8). Nevertheless, the defects of 164?
Cdk5fl/flTie2Cre mice - defective lymphatic vessel patterning with ectopic SMC coverage, 165?
arrested valve formation, lymphatic dysfunction and lymphedema - are in striking similarity to 166?
Foxc2 deficient mice 10. Foxc2 is a forkhead transcription factor crucial for lymphatic vessel 167?
 
96 8 Appendix
7?
?
development and valve formation 10,26 and is associated with human lymphedema-distichiasis 168?
27,28. In addition to lymphatic vessel defects, Foxc2 deficient mice show defects of aortic arch 169?
formation and skeletogenesis as well as cardiovascular defects. Foxc2-/- mice die within 10 170?
min after birth due to respiratory defects and cyanosis, showing overall embryonic and 171?
perinatal lethality 29,30. Thus, nevertheless, we hypothesized that Foxc2 could be the target of 172?
Cdk5 mediating its effects in the lymphatic endothelium. Foxc2 expression and 173?
electrophoretic mobility was not changed in LECs or BECs from EC-specific Cdk5 174?
knockdown embryos (Supplementary Fig. S9a-d,i). Similar expression of Foxc2 in wildtype 175?
and global Cdk5 knockout embryos (Supplementary Fig. S9j) excluded that this was due to 176?
EC contamination with other cells. In line, Cdk5 silencing in human LECs or HUVECs only 177?
slightly reduced Foxc2 (Supplementary Fig. S9e-h,k,l). Furthermore, Cdk5 downregulation 178?
did not influence Foxc2 localization (Supplementary Fig. S9m), nor Foxc2 binding to naked 179?
DNA (Supplementary Fig. S10a,b). However, Cdk5 overexpression (Supplementary Fig. 180?
S10c) significantly increased Foxc2 reporter gene activation (Fig. 6a), suggesting that Cdk5 181?
is required for Foxc2 transcriptional activity. 182?
Next, we wanted to understand how Cdk5 regulates Foxc2 activity. Recently, it has been 183?
shown that Foxc2 is phosphorylated at eight conserved serine/threonine residues, essential 184?
for Foxc2-dependent transcription but a kinase that mediates Foxc2 phosphorylation in vivo 185?
has not been identified yet 25. Coimmunoprecipitation of overexpressed or endogenous Cdk5 186?
and Foxc2 indicated their direct interaction in human LECs (Fig. 6b,c). In fact, we found that 187?
recombinant Cdk5/p35 efficiently phosphorylated Foxc2 in vitro, which was reduced by the 188?
Cdk5 inhibitor roscovitine (Fig. 6d). Arguing that Foxc2 is a direct substrate of Cdk5, Cdk5 189?
overexpression increased 32P-phosphate incorporation into Foxc2 (Fig. 6e) whereas Cdk5 190?
silencing reduced 32P-labeled Foxc2 (Fig. 6f). Importantly, Foxc2 32P-phosphate incorporation 191?
was reduced in Cdk5fl/flTie2Cre LECs in vivo (Fig. 6g). In sum, our data demonstrate that 192?
Cdk5 phosphorylates Foxc2. 193?
Interestingly, Cdk5 downregulation failed to induce a change in Foxc2 electrophoretic 194?
mobility (Supplemental Fig. S9i-l), characteristic for loss of Foxc2 phosphorylation 25. This 195?
 
8 Appendix 97
8?
?
suggests that Cdk5 does not regulate all but only (a) specific Foxc2 phosphorylation site(s). 196?
Moreover, this indicates that Foxc2 most likely gets regulated by additional other kinases 197?
besides Cdk5, i.e. ERK1/2 and cell cycle Cdks, as it was previously suggested 25. We 198?
checked whether Cdk5 collaborates with these pathways that have been associated with 199?
Foxc2 regulation, i.e. ERK1/2 and cell cycle related Cdks 25. In Cdk5fl/flTie2Cre LECs neither 200?
ERK1/2 activity or expression (Fig. 6h) nor levels of cell cycle related Cdks 1, 2, 7, 8, and 9 201?
(Fig. 6i) were changed. This suggests that Cdk5 does not cooperate with these pathways in 202?
regulating Foxc2. 203?
We finally aimed to assess the functional relevance of Cdk5-mediated Foxc2 204?
phosphorylation. Whereas Cdk5 alone did not activate the Foxc2 reporter Cdk5 significantly 205?
increased wild type Foxc2-driven reporter activation, i.e. the Cdk5-mediated increase of 206?
Foxc2 reporter activation significantly differed from the effect of Foxc2-wt alone (Fig. 6a,j). In 207?
contrast, if Cdk5 was co-expressed with Foxc2 phosphorylation mutants – pmFoxc2 with all 208?
eight serine/threonine residues mutated to alanine and Foxc2-mut?S219-366 that lacks the 209?
complete phosphorylation region (Supplementary Fig. S10d) - Cdk5 was not able to induce 210?
Foxc2 reporter activation, i.e. there was no significant difference between the Foxc2 mutants 211?
with and without Cdk5 in Foxc2 reporter activation (Fig. 6j). In line with these results, Cdk5 212?
did not interact with Foxc2 phosphorylation mutants (Fig. 6k). This demonstrates that Cdk5-213?
mediated phosphorylation is important for Foxc2 transcriptional activity. 214?
215?
Cdk5-dependent Foxc2 phosphorylation is required for Foxc2 downstream target 216?
expression.217?
Disruption in Cdk5-Foxc2 signaling should affect Foxc2 target gene expression. Connexin37 218?
(Cx37) is a downstream target of Foxc2 important for lymphatic valve formation 31,32. Similar 219?
to Foxc2-/- mice, Cdk5fl/flTie2Cre mice demonstrated attenuated Cx37 expression in lymphatic 220?
vessels, but not arteries (Fig. 7a). In line, RT-qPCR analysis revealed more than 95% down-221?
regulation of Cx37 mRNA in Cdk5fl/flTie2Cre LECs but not BECs (Fig. 7b,c). Moreover, Cdk5 222?
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silencing decreased Cx37 mRNA and protein in hLECs (Fig. 7d,e). Prox1 and VE-cadherin 223?
were analyzed as markers and confirm LEC and BEC identity (Supplementary Fig. S10e-h). 224?
Foxc2 phosphorylation was shown to selectively recruit Foxc2 to chromatin, differentially 225?
regulating expression of specific Foxc2 target genes 25. Thus, next we aimed to clarify 226?
whether Cdk5-mediated activation of Foxc2-dependent transcription is due to 227?
phosphorylation. Therefore, we investigated the influence of Cdk5 on the expression of 228?
Foxc2 target genes that have been found to be dependent or independent on Foxc2 229?
phosphorylation. Corroborating our previous results, Cdk5 silencing in hLECs decreased 230?
EPB41L5 and CSNK1G3, Foxc2 downstream target genes that require Foxc2 231?
phosphorylation 25 (Fig. 7f,g) but did not regulate BMP4 and MEF2C, Foxc2 target genes that 232?
do not depend on its phosphorylation 33 (Fig. 7h,i). Importantly, in vivo, EPB41L5 mRNA was 233?
reduced in Cdk5fl/flTie2Cre LECs (Fig. 7j). Thus, Cdk5 specifically influences expression of 234?
Foxc2 target genes that depend on Foxc2 phosphorylation, demonstrating that Cdk5 controls 235?
Foxc2-dependent transcription by phosphorylation. Foxc2 phosphorylation regulates its 236?
chromatin recruitment only in the context on native chromatin, but not in reconstituted in vitro 237?
systems 25. Therefore, although Cdk5 did not influence Foxc2 binding to naked DNA 238?
(Supplementary Fig. S10a,b), our results raise questions regarding the role of Cdk5 in the 239?
interaction of Foxc2 with DNA and transcription-associated proteins.  240?
Taken together, our results demonstrate that Cdk5 is essential for lymphatic vessel 241?
development and valve formation. We highlight Cdk5 as important player in the 242?
transcriptional control of lymphatic vessel remodeling, suggesting a function of Cdk5 in 243?
linking cell signaling and gene expression in the lymphatic endothelium. Our study provides 244?
the rationale for investigating CNS-related Cdk5-driven signaling in the context of lymphatic 245?
vessel biology with the aim to better understand the mechanism underlying human 246?
lymphedema syndromes.247?
248?
249?
Materials and Methods 250?
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251?
EC-specific Cdk5 knockout mice 252?
Mouse experiments were performed with approval by the District Government of Upper 253?
Bavaria in accordance with the German animal welfare and institutional guidelines. Tie2Cre 254?
mice were from Jackson Laboratory (B6.Cg-Tg(Tek-cre)12Flv/J, 004128). Floxed Cdk5 mice 255?
34, Tamoxifen-inducible Cdh5(PAC)-CreERT2 mice 13, and deleterCre mice 35 were 256?
described. To obtain Cdk5fl/flTie2Cre, Cdk5fl/flCdh5(PAC)-CreERT2 (Cdk5fl/flVECCre), or 257?
Cdk5fl/?Tie2Cre mice, Cdk5fl/fl or Cdk5wt/? females were crossed to Cdk5wt/flTie2Cre or 258?
Cdk5wt/flVECCre males. To induce Cdk5 downregulation, pregnant mice were injected with 259?
tamoxifen (100 μl, 10 mg/ml in peanut oil) on E10.5, E11.5, E12.5 and embryos were 260?
collected at E16.5.  261?
Primers for Genotyping: Cdk5 floxed: 5’ctgcatttctcgtccctagc3’; 5’acgcttcagagccacaatct3’. 262?
Cdk5 excised: 5’ctgcatttctcgtccctagc3’; 5’ggccctgctttgtatctctg3’. Tie2Cre: 263?
5’gctgccacgaccaagtgacagcaatg3’; 5’gtagttattcggatcatcagctacac3’. Cdh5(PAC)-CreERT2 and 264?
deleterCre: 5’gcctgcattaccggtcgatgcaacga3’; 5’gtggcagatggcgcggcaacaccatt3’.  265?
 266?
Tracer experiments 267?
Evans blue (1% in PBS, E2129 Sigma) or FITC-lectin (1 mg/ml in PBS, L9381 Sigma) was 268?
injected intravenously (LV/BV separation; E16.5 embryos: periorbital sinus, 3 μl; 269?
anesthesized adult mice: tail vein, 250 μl) or subcutaneously (LV function; E16.5 embryos 3 270?
μl; anesthesized adult mice: hind paw, 100 μl). Olympus SZX7/SZ-BI30 stereomicroscope, 271?
Olympus DP25 camera, CellSens software version 1.3.  272?
273?
Stainings274?
Immunohistochemistry. For paraffin sections, tissues were fixed with 4% formalin for 24 h, 275?
left in 1%formalin, paraffin embedded, and sectioned (5 μm). For cryosections, tissues were 276?
frozen into TissueTek. 10 μm sections were prepared and fixed with formalin 4% (10 min, 277?
RT). Sections were blocked (1% BSA/PBS), incubated with primary antibodies (2h RT or o/n 278?
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4°C), washed, incubated with AlexaFluor-labeled secondary antibodies (45min, RT, Life 279?
Technologies) and Hoechst 33342 (5 μg/ml) or detection was performed using Vectastain 280?
ABC Kit and ImmPACT AEC Peroxidase Substrate Kit (Biozol), and mounted (Fluorsave 281?
Reagent, Calbiochem). For TUNEL staining, ApopTag Plus Fluorescein In Situ Apoptosis 282?
Detection Kit (S7110, Millipore) was used. Liver: 4 mice, 60 fields; brain: 4 mice, 30 fields; 283?
spinal column: 3 mice, 6 fields per genotype. Proliferating Ki67-positive cells. E16.5: 3 mice, 284?
36 pictures; E13.5: 5 mice, at least 47 pictures per genotype. 285?
Whole mount staining. Tissues were fixed (formalin 4%, 30min, RT or methanol 5min, -286?
20°C), washed, blocked (1h, RT, 0.5% TritonX, 2% BSA/PBS), incubated with primary 287?
antibodies (o/n, 4°C), washed, incubated with AlexaFluor-labeled secondary antibodies (2h, 288?
RT), and mounted. Valve analysis was done in back skin and intestines of E16.5 and E18.5 289?
embryos 31. E16.5: 9 embryos; E18.5: 5 embryos per genotype. Numbers of valves at 290?
specific stages were calculated in 10 fields (skin) or 4 mesenteric branches per embryo. 291?
Primary antibodies: CD31 (553370, BD Pharmingen), Cdk5 (AHZ0492, Life Technologies), 292?
Connexin37 31, endomucin (sc-65495, Santa Cruz), EphB4 (AF446, R&D Systems), ephrinB2 293?
(AF496, R&D Systems), Ets1 (sc-350, Santa Cruz), Ets2 (sc-351, Santa Cruz), Foxc2 31, 294?
Ki67 (ab15580, abcam), Lyve1 (ab14917, abcam), p35 (sc-820 Santa Cruz), podoplanin (sc-295?
134483, Santa Cruz), Prox1 (AF2727, R&D Systems), ?-SMA (C6198, Sigma), VEGFR3 296?
(AF743, R&D Systems).  297?
Pictures were taken with an Olympus BX41 microscope or with a Zeiss LSM 510 META 298?
confocal microscope. ImageJ and the particle counter plugin were used for counting. 299?
Lymphovenous valve staining: Wholemount staining of E12.5 embryos was performed as 300?
previously described 3. In brief, embryos were fixed (2h RT), permeabilized (0.5%TX in PBS, 301?
4°C, 48h), blocked (1% BSA, 0.1% Tween20 in PBS, 4°C, 48h), incubated with primary 302?
antibodies (anti-Prox1, 102-PA32 Relia Tech; anti-CD31 553370 BD Biosciences; anti-303?
VEGFR3, AF743 R&D Systems) in blocking solution (4°C, 1 week), washed (0.1% Tween in 304?
PBS, 2d), incubated with secondary antibodies (Alexa Flour, Life Technologies), and washed 305?
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(0.1% Tween in PBS, 2d) befor clearing with BABB. Embryos were imaged using a Leica 306?
SP8 SMD confocal microscope with appropriate software. 307?
308?
Isolation of mouse endothelial cells 309?
Liver sinusoidal endothelial cells (LSECs) were isolated according to manufacturer’s 310?
instructions (Milteny Biotech miniMACS Separation System). LECs and BECs were isolated 311?
from embryo skin as described 31 and cultured with EGM2 (Lonza). 312?
 313?
Cell culture 314?
HUVECs were cultured as described 36. Human telomerase-immortalized LECs (hLECs, S. 315?
Geleff, University of Vienna, Vienna, Austria) 37,38 were cultivated in EGM2-MV (Lonza) and 316?
HepG2 cells (ATCC) in DMEM/10% FCS. 317?
 318?
Cell transfection 319?
The amaxa system (Lonza) with HUVEC nucleofector kit (VPB-1002, ECs) or cell line kit T 320?
(VCA-1002, HepG2) and indicated siRNAs was used 36. Plasmids: Cdk5 (addgene 1871), 321?
p35 (addgene 1347), Foxc2 33, Foxc2-mutA8 and Foxc2-mut?219-366 25. Adenoviral 322?
transduction: Sirion Biotech GmbH (Martinsried, Germany). 323?
 324?
RT-PCR 325?
mRNA isolation was done with Qiagen RNeasy Mini Kit, reverse transcription with High-326?
Capacity cDNA Reverse Transcription Kit (Applied Biosystems), and RT-PCR with the 7300 327?
Real Time PCR System. Taqman gene expression assays: BMP4 Mm00432087_m1, 328?
connexin37 Hs00704917_s1 and Mm00433610_s1, Cdk5 Hs00358991_g1 and 329?
Mm01134945_g1, CSNK1G3 Mm00666283_m1, EPB41L5 Mm00521096_m1, Foxc2 330?
Hs00270951_s1 and Mm00546194_s1, MEF2C Mm01340842_m1, Prox1 Hs00896294_m1 331?
and Mm00435969_m1, VE-cadherin Mm00486938_m1 (Applied Biosystems). GAPDH was 332?
used as housekeeper. 333?
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Immunoblotting335?
Immunoblotting was described 36. Primary antibodies: actin (MAB 150 1R, Chemicon), Cdk1 336?
(9116, Cell Signalling), Cdk2 (sc-163, Santa Cruz), Cdk5 (AHZ0492, Life Technologies), 337?
Cdk7 (2916, Cell Signalling), Cdk8 (sc-1521, Santa Cruz), Cdk9 (sc-13130, Santa Cruz), 338?
ERK (p44/p42 MAPK, 9202, Cell Signalling), ERK-phspho (p44/p42 MAPK, 9206, Cell 339?
Signalling), Ets1 (sc-350, Santa Cruz), Ets2 (sc-351, Santa Cruz), (Foxc2 (AF5044, R&D 340?
Systems), Lyve1 (ab14917, R&D Systems), podoplanin (sc-134483, Santa Cruz), Prox1 341?
(AF2727, R&D Systems), VEGFR3 (AF743, abcam).  342?
 343?
Immunoprecipitation344?
After cell lysis, Cdk5 or Foxc2 antibodies were added. After incubation (o/n, 4°C), ProteinG 345?
beads (50 μl per sample, P3296, Sigma) were added. After incubation (3h, 4°C), proteins 346?
were extracted and subjected to immunoblotting. 347?
 348?
Luciferase reporter assay 349?
HepG2 cells were transfected as indicated. Luciferase plasmids were 6xFOXC2-luc-reporter 350?
(firefly) 33 pGL4.74[hRluc/TK] (Renilla, Promega). Dual-Luciferase® Reporter Assay System 351?
(Promega) and an Orion II Microplate Luminometer (Berthold) were used. 352?
353?
Electrophoretic mobility shift assay (EMSA) 354?
EMSA was described 39. Foxc2 oligonucleotides: 5’gatcccttaagtaaacagcatgagatc3’, 355?
5’gatctcatgctgtttacttaagggatc3’ (Biomers).356?
357?
Kinase assay 358?
Recombinant Foxc2 (H00002303, Abnova) and Cdk5/p35 (14-477, Millipore) were incubated 359?
with 32P-ATP (Hartmann Analytic) with/without roscovitine (100 μM, R7772, Sigma-Aldrich). 360?
SDS-PAGE and autoradiography were performed. 361?
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362?
Phosphate incorporation 363?
HUVECs or human LECs were transfected as indicated. Primary LECs were isolated from 364?
embryo skin. 18h after transfection or isolation, cells were incubated with 32P orthophosphate 365?
(NEX053010MC, PerkinElmer) for 12h in phosphate-free medium (DMEM, 11971, Gibco). 366?
Foxc2 immunoprecipitation, SDS-PAGE and autoradiography were performed. 367?
 368?
Statistics369?
Numbers of independently performed experiments are indicated in the figure legends. Graph 370?
data represent means ± SEM. Statistical analysis was performed using SigmaStat software 371?
Version 3.1. 372?
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 500?
Figure Legends 501?
Figure 1. Endothelial cell specific Cdk5 knockout mice. (a) Impaired survival of 502?
Cdk5fl/flTie2Cre mice. 40% Cdk5fl/flTie2Cre mice died during the first 2 days, 75% during the 503?
first 30 days after birth. 352 mice; 54 Cdk5fl/flTie2Cre mice. (b) Reduced size of 504?
Cdk5fl/flTie2Cre mice (d11). (c) Reduced body weight of Cdk5fl/flTie2Cre mice. *p?0.05; n?4 505?
per age and genotype. (d) Intestinal bleedings of Cdk5fl/flTie2Cre mice (d20). (e) Embryonic 506?
lethality of Cdk5fl/flTie2Cre embryos. Percent of living Cdk5fl/flTie2Cre embryos at indicated 507?
stages. (f-h) Blood-filled leaky superficial capillaries, bleedings, and edema formation in EC-508?
specific Cdk5 knockout embryos. (f) E15.5 and E16.5 Cdk5fl/flTie2Cre embryos. (g) E16.5 509?
Cdk5fl/flVECCre embryos. (h) E15.5 Cdk5?/flTie2Cre embryos. (i) Decreased Cdk5 levels in 510?
LECs (29%) and BECs (41%) of E16.5 Cdk5fl/flTie2Cre embryos. *p?0.001; n=8 per 511?
genotype. (j) Decreased Cdk5 levels in LECs (7.8%) and BECs (6.4%) of E15.5 512?
Cdk5?/flTie2Cre embryos. *p?0.001; n=3 per genotype. 513?
 514?
Figure 2. Defective lymphatic vessel (LV) development and function in EC-specific 515?
Cdk5 deficient mice. (a) LVs of Cdk5fl/flTie2Cre embryos are dilated and contain blood cells. 516?
Staining of E16.5 transverse sections for endomucin (green, blood vessels), Lyve1 (red, LVs) 517?
and Hoechst 33342 (blue) show superficial vessels in the skin. n=5 per genotype. Scale bar 518?
20 μm. (b-d) Primary lymph sacs (LS) of Cdk5fl/flTie2Cre embryos are dilated and filled with 519?
blood. (b) Haematoxylin/Eosin (H/E) staining of E16.5 transverse sections at jugular regions. 520?
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Scale bar 200 μm. (c) Transverse sections at jugular regions of E16.5 embryos were stained 521?
for Lyve1 (red). Scale bar 100 μm. (b,c) n=6 per genotype. (d) Quantification of LS length 522?
and width. *p?0.05. n=3 per genotype. (e-g) Patterning defects and ectopic SMC coverage of 523?
Cdk5fl/flTie2Cre LVs. (e) Whole mount staining of E16.5 skin for Prox1 (green), Lyve1 (blue), 524?
?-SMA (red). Scale bar 100 μm. (f) LV dilation of Cdk5fl/flTie2Cre embryos indicated by an 525?
increased LV area. (g) Decreased LV branching of Cdk5fl/flTie2Cre embryos. (f,g) *p?0.01. 526?
n=9 per genotype. (h) Abnormal connection between LVs and blood vessels (BVs) in 527?
Cdk5fl/flTie2Cre embryos. Intravenous injected FITC-lectin (green) exclusively stained BVs 528?
(CD31, red) of control embryos but labeled large collecting LVs (Lyve1, blue) in 529?
Cdk5fl/flTie2Cre embryos. n=3 per genotype. Scale bar 20 μm. (i) Communication between 530?
lymphatic and blood vessels persisted in adult mice. Intravenous injected Evans blue dye 531?
exclusively labeled arteries (A) and veins (V) in control mice. In Cdk5fl/flTie2Cre mice the dye 532?
also reached collecting mesenteric LVs (L). n=3 per genotype. Age: d20-25. Scale bar 2 mm. 533?
(j,k) Impaired LV draining function in Cdk5fl/flTie2Cre mice. (j) Subcutaneously injected Evans 534?
blue was not removed from the injection site (asteriscs) in E16.5 Cdk5fl/flTie2Cre embryos. 535?
n=3 per genotype. Scale bar 0.5 mm. (k) Subcutaneously injected Evans blue (hind paw) 536?
was not drained away from the injection site in Cdk5fl/flTie2Cre mice, but labels tortuous LVs. 537?
n=3 per genotype. Age: d20-25. Scale bar 1 mm. 538?
 539?
Figure 3. Defective lymphatic valve formation and maturation in endothelial-specific 540?
Cdk5 knockout embryos. (a) Cdk5 expression in lymphatic valves. Whole mount stainings 541?
of E18.5 mesenteric vessels show colocalization of Cdk5 (green) and Prox1 (red) 542?
(arrowheads). n=3. (b) Schematic illustration of the stages of lymphatic valve morphogenesis 543?
according to 31. Stage 1: Initiation of lymphatic valve formation. LEC clusters express high 544?
levels of Prox1. Stage 2: Ring-like valve structures of Prox1-high-expressing LECs are 545?
established. Stage 3: Leaflet formation starts by invagination of cells into the lumen. (c-f) 546?
Cdk5 controls lymphatic valve formation. Stainings of (c) skin and (d) mesenteric vessels of 547?
E16.5 embryos for Prox1 (green), Foxc2 (blue) and ?-SMA (red). Valve stages are indicated 548?
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by numbers. n=9 per genotype. Scale bar 50 μm. (e,f) Quantification of valves at specific 549?
stages in E16.5 embryos. n=9 per genotype. Percentage of valves in respective stages are 550?
indicated. (e) skin; *p?0.001. (f) mesenteric vessels; *p?0.001. (g-j) Cdk5 controls lymphatic 551?
valve maturation. Stainings of (g) skin and (h) mesenteric vessels of E18.5 embryos for 552?
Prox1 (green), Foxc2 (blue) and ?-SMA (red). Valve stages are indicated by numbers. n=5 553?
per genotype. Scale bar 50 μm. (i,j) Quantification of valves at specific stages in E18.5 554?
embryos. Impaired valve maturation is indicated by reduced numbers of valves at stages 2 555?
and 3. (i) skin; total *p?0.05; stage 2 *p?0.001; stage 3 *p?0.05. (j) mesenteric vessels; total 556?
*p?0.05; stage 2 *p?0.001; stage 3 *p?0.05. (i,j) n=5 per genotype. Percentage of valves in 557?
respective stages are indicated.  558?
 559?
Figure 4. Endothelial Cdk5 knockout embryos frequently show impaired 560?
lymphovenous valve formation. Sagittal views of control and Cdk5fl/flTie2Cre embryos 561?
(E12.5) wholemount immunostained for CD31 (green), VEGFR3 (blue) and PROX1 (red) are 562?
shown (left panels). Two contact sites between pTD and CV that express high levels of 563?
Prox1 indicate lymphovenous valves (arrowheads). Individual optical sections (right panels) 564?
through the contact area of pTD and CV are shown. In the control, two areas with a double 565?
layer of endothelial cells that express high levels of Prox1 indicate lymphovenous valves 566?
(arrowheads). control: n=4. 3 out of 5 analyzed Cdk5fl/flTie2Cre embryos showed defects in 567?
lymphovenous valve formation.  568?
 569?
Figure 5. Cdk5 is not essential for valve maintenance. (a) Normal lymphatic vessels in 570?
postnatally induced endothelial Cdk5 knockout mice. Mesentery of d10 control and 571?
Cdk5fl/flVECCre pups treated with tamoxifen (d1-d3). Lymphatic vessel (L), artery (A) and 572?
vein (V) are indicated. n=2 per genotype. Scale bar 2 mm. (b) Normal lymphatic valves in 573?
postnatally induced endothelial Cdk5 knockout mice. Staining of mesentery of d10 control 574?
and Cdk5fl/flVECCre pups for Prox1 (green) and ?-SMA (red). n=2 per genotype. Scale bar 575?
50 μm. 576?
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Figure 6. Cdk5 controls Foxc2 by phosphorylation. (a) Cdk5 activates the Foxc2 578?
luciferase reporter. Foxc2 reporter activity was analyzed after cotransfection of HepG2 cells 579?
with empty vector, Foxc2, Cdk5/p35, or Foxc2 and Cdk5/p35. *p<0.05. n=5. (b,c) Interaction 580?
of Cdk5 and Foxc2. Immunoprecipitations of Foxc2, Cdk5, and IgG of (b) hLECs 581?
overexpressing Foxc2 and Cdk5/p35 or (c) untreated hLECs. (B,C) n=3. IP: 582?
immunoprecipitation. SN: supernatant. (d) Cdk5 phosphorylates Foxc2 in vitro. Recombinant 583?
Foxc2 and Cdk5/p35 were incubated with 32P-ATP with/without the Cdk5 inhibitor roscovitine 584?
(rosco, 100μM). SDS-PAGE and autoradiography were performed. n=2. (e-g) Cdk5 585?
phosphorylates Foxc2 in vivo. (e) Cdk5 overexpression increases Foxc2 32P incorporation. 586?
HUVECs overexpressing Foxc2 with/without Cdk5/p35. * p<0.01. n=3. (f) Cdk5 587?
downregulation decreases Foxc2 32P incorporation. HUVECs transduced with non-targeting 588?
(nt) or Cdk5 shRNA and transfected with Foxc2. *p<0.05. n=2. (g) Foxc2 32P incorporation in 589?
E16.5 control and Cdk5fl/flTie2Cre LECs. *p<0.05, n=3 per genotype. (h) Phosphorylated 590?
ERK (pERK) and ERK are not changed in E16.5 Cdk5fl/flTie2Cre LECs. n=2 per genotype. (i) 591?
Levels of Cdks1, 2, 7, 8, 9 are not changed by Cdk5 silencing in hLECs. (j) Cdk5-mediated 592?
phosphorylation controls Foxc2 transcriptional activity. Foxc2 reporter gene activity was 593?
analyzed after cotransfection of HepG2 cells with empty vector, Foxc2, pmFoxc2, or Foxc2-594?
mut?S219-366 (Foxc2-?), with/without Cdk5/p35. Cdk5 induces Foxc2 reporter activation 595?
when coexpressed with Foxc2. When cotransfected with Foxc2 phosphorylation mutants 596?
pmFoxc2 or Foxc2-?, Cdk5 did not induce Foxc2 reporter activation. * p<0.001. n=4. (k) 597?
Interaction of Cdk5 with Foxc2 and Foxc2 phosphorylation mutants. Immunoprecipitations of 598?
Cdk5 (or IgG as control) from hLECs overexpressing Cdk5/p35 together with either Foxc2, 599?
pmFoxc2, or Foxc2-mut?S219-366 were performed. Cdk5 coprecipitates with Foxc2, but not 600?
with pmFoxc2, or Foxc2-mut?S219-366. n=3. IP: immunoprecipitation. SN: supernatant. 601?
 602?
Figure 7. Cdk5 regulates Foxc2 downstream target expression. (a) The Foxc2 603?
downstream target connexin37 (Cx37) is decreased in LVs (L) but not arteries (A) of 604?
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Cdk5fl/flTie2Cre embryos. Whole mount stainings of E16.5 mesentery for Cx37 (green), Prox1 605?
(blue), and ?-SMA. Lower panels show high magnification pictures. n=4 per genotype. Scale 606?
bars 20 μm. (b,c) Cx37 mRNA is significantly decreased in (b) Cdk5fl/flTie2Cre LECs but not 607?
(c) BECs. *p?0.001. n=5 per genotype. (d) Cdk5 silencing decreases Cx37 mRNA in hLECs. 608?
*p?0.05. n=4. (e) Cdk5 silencing decreases Cx37 protein in hLECs. n=2. (f,g) Expression of 609?
the Foxc2 downstream target genes EPB41L5 and CSNK1G3 is decreased in Cdk5 siRNA 610?
treated hLECs. (f) EPB41L5 *p?0.05. n=4. (g) CSNK1G3 *p?0.05. n=5. (h,i) Expression of 611?
the Foxc2 downstream target genes (h) BMP4 and (I) MEF2C is not changed in Cdk5 siRNA 612?
treated hLECs. (h,i) ns not significant, each n=3. (j) EPB41L5 mRNA is decreased in E16.5 613?
Cdk5fl/flTie2Cre LECs. *p?0.001. n=4 per genotype.  614?
615?
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Supplementary Figure Legends 
Supplementary Figure S1. Expression of Cdk5 in the mouse endothelium. (a,b) Cdk5 is 
ubiquitously expressed in the endothelium. Transverse sections of E16.5 embryos were 
stained for Cdk5 (green) and CD31 (red) or Lyve1 (red). Cdk5 is expressed in endothelial 
cells of (a) large arteries, veins, blood vessel capillaries (arrowheads), and (b) large 
collecting lymphatic vessels and lymphatic capillaries (arrowheads). n=3. Scale bar 20 μm. 
(c,d) p35 is ubiquitously expressed in the endothelium. Transverse sections of E16.5 
embryos were stained for p35 (green) and CD31 (red) or VEGFR3 (red). p35 is expressed in 
endothelial cells of (c) large arteries, veins, blood vessel capillaries (arrowheads) and (d) 
lymphatic vessels. n=3.  
Supplementary Figure S2. Knockdown of Cdk5 in the mouse endothelium. (a) Gene 
targeting strategy. (b) PCR genotyping of Cdk5 wildtype (wt; 392 bp) and floxed (fl; 464 bp) 
alleles. (c) Cdk5 expression is decreased in liver sinusoidal endothelial cells (LSECs) from 
adult endothelial-specific Cdk5 knockout mice (Cdk5fl/flTie2Cre genotype). Western blots for 
Cdk5 and actin. *p?0.001. n=8 per genotype. (d) Cdk5 expression is decreased in LSECs 
from adult inducible endothelial-specific Cdk5 knockout mice (Cdk5fl/flVECCre; 
Cdk5fl/flCdh5(PAC)-CreERT2 genotype) after tamoxifen treatment. Western blots for Cdk5 
and actin. *p?0.01. n=5 per genotype. (e) Images show bleedings (arrows) in the skin and 
intestines of newborn Cdk5fl/flTie2Cre pups. 
 
Supplementary Figure S3. Downregulation of Cdk5 in the mouse endothelium. (a,b) 
Cdk5 is expressed in blood (a) and lymphatic (b) vessel ECs of control embryos and is 
decreased in the endothelium of Cdk5fl/flTie2Cre embryos. Transverse sections of E16.5 
embryos were stained for Cdk5 (green) and CD31 (red) or Lyve1 (red). Insets are presented 
in higher magnification on the right. n=3 per genotype. Scale bars 20 μm. (c) Cdk5 
expression is decreased in BECs and LECs of E14.5 Cdk5fl/flTie2Cre embryos. Actin 
indicates equal loading. n=2 per genotype. 
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Supplementary Figure S4. Blood vessel phenotype of endothelial Cdk5 knockout 
embryos. (a-d) Arterial and venous cell fate specification in Cdk5fl/flTie2Cre embryos. 
Transverse sections of control and Cdk5fl/flTie2Cre embryos at (a,b) E13.5 and (c,d) E16.5 
were stained for the arterial marker ephrinB2 together with CD31 or the venous marker 
EphB4 and CD31. Arteries of control and Cdk5fl/flTie2Cre embryos show comparable 
expression of ephrinB2 (a,c), veins show comparable expression of EphB4 (b,d). (a-d) n=3 
per genotype each. Scale bar 20 μm. (e-g) Coverage of blood vessels with SMC is not 
changed in Cdk5fl/flTie2Cre embryos. (e) Transverse sections of E13.5 embryos were stained 
for ?-SMA and endomucin. n=3 per genotype. Scale bar 50 μm. (f) Transverse sections of 
E16.5 embryos were stained for ?-SMA and endomucin. n=3 per genotype. Scale bar 50 μm. 
(g) Whole mount stainings of dorsal skin of E16.5 embryos for ?-SMA and CD31. n=9 per 
genotype. Scale bar 50 μm.
Supplementary Figure S5. Abnormal development, non-separation, and dysfunction of 
lymphatic vessels in EC-specific Cdk5 deficient mice. (a) Dilated vessels in the skin of 
EC-specific Cdk5 knockout embryos. Haematoxylin/Eosin (H/E) staining of transverse 
paraffin sections of E16.5 embryos was performed. Scale bar 100 μm. n=6 per genotype. (b) 
Lymphatic vessels (LV) of Cdk5fl/flTie2Cre embryos are dilated and contain blood cells. 
Staining of E16.5 transverse sections for endomucin (green, blood vessels), Lyve1 (red, 
lymphatic vessels) and Hoechst 33342 (blue). Large collecting lymphatic vessels of E16.5 
control and Cdk5fl/flTie2Cre embryos are shown. n=5 per genotype each. Scale bar 20 μm. 
(c) Abnormal connection between LVs and blood vessels (BVs) in Cdk5fl/flTie2Cre embryos. 
Single channels referring to Fig. 2h. Intravenous injected FITC-lectin (green) exclusively 
stained BVs (CD31, red) of control embryos but labeled large collecting LVs (Lyve1, blue) in 
Cdk5fl/flTie2Cre embryos. n=3 per genotype. Scale bar: 20 μm. (d,e) Superficial lymphatic 
capillaries of both control littermates and Cdk5fl/flTie2Cre embryos are not reached by 
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intravenously injected (d) FITC-lectin (scale bar: 20 μm) or (e) Evans blue. Scale bar 1 mm. 
n=3 per genotype each. 
 
Supplementary Figure S6. Endothelial knockdown of Cdk5 does not induce apoptosis, 
but leads to lymphatic vessel hyperplasia. (a-d) Apoptosis is not changed in 
Cdk5fl/flTie2Cre mice. TUNEL staining of transverse paraffin sections of E16.5 embryos. (a) 
Staining of E16.5 skin for TUNEL (green), Collagen IV (red), Hoechst 33342 (blue). 3 mice 
per genotype. Staining of rat mammary gland sections served as a positive control. Scale bar 
20 μm. (b-d) Numbers of TUNEL-positive cells in (b) liver, (c) brain, and (d) spinal column. 
(b,c) 4 mice per genotype. (d) 3 mice per genotype. ns: not significant. (e-h) Lymphatic 
vessel hyperplasia in endothelial Cdk5 knockout mice. Quantification of Prox1 positive cells 
in (i) E16.5 skin (t-test, *p?0.05, n=9 per genotype) (j) E16.5 intestines (t-test, *p?0.05, 
control: n=10, Cdk5fl/flTie2Cre n=9), (k) E18.5 skin (ns, control: n=6, Cdk5fl/flTie2Cre n=5), 
and (l) E18.5 intestines (ns, n=5 per genotype). ns: not significant. 
Supplementary Figure S7. Defective lymphatic valve formation and maturation in EC-
specific Cdk5 knockout embryos. (a-d) Defective valve formation and maturation in 
Cdk5fl/flTie2Cre embryos. Staining of (a) E16.5 skin and (b) mesenteric vessels, as well as 
(c) E18.5 skin and (d) mesenteric vessels for Prox1 (green), Foxc2 (blue; strong phenotype) 
or LYVE1 (blue, mild phenotype), and ?-SMA (red). Overview pictures. Scale bars 100 μm. 
Numbers indicate valve stages. (a,b) n=9 per genotype. (c,d) n=5 per genotype. (e) 
Defective valve formation in Cdk5fl/flVECCre embryos. Whole mount staining of E16.5 skin for 
Prox1 (green) and ?-SMA (red). Scale bar 100 μm. Numbers indicate valve stages. n=2 per 
genotype. 
Supplementary Figure S8. Expression of LEC specific genes is not influenced by Cdk5 
knockdown. (a) Immunoblots show expression of Foxc2, Ets1, Ets2, Lyve1, Podoplanin, 
Prox1, and VEGFR3 in LECs from E14.5 embryos with control and Cdk5fl/flTie2Cre 
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phenotype. n=2 per genotype. (b) Whole mount stainings of E16.5 mesenteries show 
expression of Foxc2, Ets1, Ets2, Podoplanin, Prox1, and VEGFR3 in control and 
Cdk5fl/flTie2Cre embryos. Cdk5 is decreased in E16.5 Cdk5fl/flTie2Cre embryos. Scale bar 
50μm. n=2 per genotype and staining. 
 
Supplementary Figure S9. Cdk5 does not influence Foxc2 expression. (a-d) Foxc2 
mRNA is not decreased in (a) LECs and (c) BECs of E16.5 Cdk5fl/flTie2Cre embryos. ns: not 
significant. n=5 per genotype. Decreased Cdk5 mRNA in (b) LECs and (d) BECs of E16.5 
Cdk5fl/flTie2Cre embryos. *p?0.001. n=5 per genotype. (e,f) Foxc2 mRNA is slightly 
decreased in hLECs treated with Cdk5 siRNA. (e) Foxc2 mRNA. *p?0.05. n=4. (f) Reduced 
Cdk5 mRNA. *p?0.05. n=4. (g,h) Foxc2 mRNA is not decreased in HUVECs treated with 
Cdk5 siRNA. (g) Foxc2 mRNA. ns: not significant. n=3. (h) Decreased Cdk5 mRNA. 
*p?0.001. n=3. (i) Foxc2 protein is not decreased in LECs and BECs from E16.5 
Cdk5fl/flTie2Cre embryos. Western blots for Lyve1 and Prox1 confirm LEC identities. Cdk5 
expression is reduced. Actin indicates equal loading. Quantitative evaluation is displayed. ns: 
not significant. n= 4. (j) Foxc2 protein is not decreased in standard Cdk5 knockout embryos. 
Western blots for Foxc2, Cdk5 and actin (loading control) from lysates from wildtype 
(Cdk5+/+) and standard Cdk5 knockout (Cdk5-/-) embryos at E16.5. Quantitative evaluation 
is displayed. 2 embryos per genotype. (k,l) Cdk5 siRNA does not decrease Foxc2 protein in 
(k) hLECs and (l) HUVECs. Western blots for Foxc2, Cdk5, and actin are displayed. 
Quantitative evaluations are shown. ns: not significant. n=3 each. (m) Cdk5 silencing does 
not influence Foxc2 localization. HUVECs treated with non-targeting (nt) or Cdk5 siRNA were 
stained for Foxc2 (green). Hoechst33342 staining shows nuclei (blue). Scale bar 20 μm. n=2. 
 
Supplementary Figure S10. Cdk5 does not influence binding of Foxc2 to naked DNA, 
but regulates Foxc2 reporter activation and target expression. (a,b) Foxc2 binding to 
naked DNA is not changed by Cdk5 silencing. (a) Foxc2 electromobility shift assays (EMSA) 
from HUVECs treated with non-targeting (nt) or Cdk5 siRNA. Foxc2 supershift indicates 
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specificity. n=5. (b) Transfection control: Western blots from HUVECs treated with non-
targeting (nt) or Cdk5 siRNA. (c) Transfection control to Fig. 6a. Western blots from HepG2 
cells after cotransfection with empty vector, Foxc2, or Cdk5/p35. (d) Transfection control to 
Fig. 6j. Western blots from HepG2 cells after cotransfection with empty vector, Cdk5/p35, 
Foxc2, pmFoxc2, or Foxc2-mut?S219-366 (Foxc2-mut?). (e) Prox1 mRNA is decreased in 
LECs of Cdk5fl/flTie2Cre embryos. *p?0.01. n=5 per genotype. (f) Cdk5 silencing 
downregulates Prox1 mRNA in hLECs. Prox1 mRNA expression in hLECs treated with non-
targeting (nt) or Cdk5 siRNA is shown. *p?0.05. n=4. (g,h) Expression of VE-Cadherin is not 
changed in Cdk5fl/flTie2Cre embryos. (g) VE-Cadherin (VEC) mRNA is not significantly 
reduced in E16.5 Cdk5fl/flTie2Cre embryos. n=5 per genotype. (h) Whole mount stainings of 
E16.5 skin reveal no obvious change in VE-cadherin (green) expression in lymphatic vessels 
of Cdk5fl/flTie2Cre embryos. Scale bar 20 μm. n=3 per genotype. 
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